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Abstract 
Breast cancer is a common disease in women worldwide. The variation of female 
breast cancer incidence in different countries is striking. The lifetime risk of 
developing breast cancer is 1 in 8 in western nations, and 1 in 24 in Hong Kong. 
Ductal carcinoma is the prevalent type comprises about 80% of the disease. 
Although tremendous effort has been put on the studies of breast cancer 
tumorigenesis, the exact mechanism is still not well understood. Studies on allelic 
aberrations involved in breast cancer of the patients in our locality are rare. In order to 
reveal the genetic alterations on local incidence, a high-resolution allelotyping analysis 
was conducted on 26 cases of breast cancer confined to the local Chinese patients with 
infiltrative ductal carcinoma of the breast, which is the most common type of breast 
cancer. 
In the current study, high frequencies of allelic imbalances were observed on 
chromosome 17p (88%), 8p (62%), 16q (58%), Iq (50%), and 17q (50%). Other 
chromosomal arms with frequent allelic imbalances were Ip, 8q, 14q, and 22q, 
observed in 46% of cases, and 5q, 6q，lOq, l lq, 12q, and 13q, observed in 42% of cases. 
Allelic imbalance frequencies on different chromosomal arms were comparable to 
previous reports, suggesting similar pathways of breast cancer tumorigenesis amongst 
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Western and Oriental populations. Eight minimal deletion regions were identified on 
chromosomes 6q24.1-25.2, 8p23.3-22, 8p21.3-12, 10q22.l-23.33，13ql2.3-14.11, 
13q 14.2-22.1，14q22.3-24.2 and 16q21-23.1. A number of candidate tumor suppressor 
genes that may play roles on breast cancer are resided in these regions. This 
information provides a background on genetic basis for further studies of breast cancer 
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CHAPTER I: INTRODUCTION 
I. AIM OF STUDY 
Globally, breast cancer is the most common form of cancer among women. 
However, the incidence rates of breast cancer are much higher in western countries 
comparing to oriental countries. Previous reports on breast cancers were plentiful, but 
molecular analyses on eastern populations were rare. In the current study, a 
high-resolution allelotyping analysis on 22 autosomes with 382 fluorescent 
microsatellite markers was carried out. 
The aims of the current research on breast cancer were (1) to provide a background “ 
information of genetic changes in breast cancer; (2) to identify potential regions 
harboring candidate genes responsible for breast tumorigenesis. The objects were 
confined to local Chinese patients, a population with low incidence rates of breast 
cancers. Furthermore, the tumor type was confined to infiltrative ductal carcinoma of 
the breast, which was the most common type of the disease worldwide. The data may 
provide important information for further investigations on breast tumorigenesis, 
especially on local Chinese breast cancer patients. 
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11. LITERATURE REVIEW 
1. Epidemiology 
Breast cancer is a major global public health problem. It is the third most 
common cancer worldwide, after cancers of the lung and stomach (Parkin et al, 1999). 
The variation of female breast cancer incidence in different countries is striking. 
The highest rates reported are for white or Hawaiian women in the United States. The 
rates are significantly reduced for women in Africa and Asia (WHO, 1997.). 
In western industrialized nations, breast cancer is the most prevalent malignancy in 
women. It accounts for about one third of all incident cancers of women in the United 
States. The estimated new breast cases and deaths are 203,500 and 39,600 in 2002 
(Jemal et al, 2002). The probability of developing invasive breast cancers up to 75 
years of age is 1 in 8. The lifetime risk to be died of the disease is around 3.4%. It is 
the second leading cause of cancer deaths in women of United States, which is preceded 
by lung cancer. The relative survival rates for women acquiring the disease are 96%, 
79%, 67%, and 60% for 1，5，10，and 15 year survival (Wingo et al, 1998). 
The incidence of breast cancer, on the other hand, is much lower in Oriental, 
including Hong Kong, and in developing countries. In Hong Kong, there were 1,787 
newly diagnosed breast cancer cases and 395 deaths registered in 1999 (Hong Kong 
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Cancer Registry, 1998-1999). It is the third leading cause of cancer deaths in women 
of Hong Kong, preceded by lung and colon cancer. The lifetime risk up to 75 years 
old to acquire breast cancer is 1 in 24 and approximately 1% to be die of it. 
Breast cancers can affect women of all races. It is rarely found before the age of 
25 except in certain familial cases. The peak incidence is at and after the menopause. 
Men are not free from the disease, but relatively at a much lower risk. In United 
States, male breast cancer accounts for about 1% of all breast cancers (Jemal et al, 
2002). Survival rates for men is worse, probably due to later stages of the disease 
when discovered (Goss et al, 1999). 
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2. Etiology 
Different etiological factors have been reported to be involved in the causes of 
breast cancers. Risk factors of the disease can be classified into heredity, hormonal, 
and environmental. 
A. Heredity 
i. Family History 
Women with a family history of breast cancer have an increased risk of acquiring 
the disease, especially in a first-degree relative. The risk will be even higher provided 
that more than one affected first degree relative, or if the relative developed breast 
cancer bilaterally, or at an early age onset (Hulka & Stark，1995) (Kelsey et al, 1993). 
ii. Inherited Predisposition 
The breast cancer susceptibility genes BRCAl and BRCA2 represent the most 
concerned targets. Their mutations occur in less than 1% of the general population 
(Whittemore et al, 1997). It has been shown that approximately 5-10% of breast 
cancer cases result from inherited mutations in breast cancer susceptibility genes (Burke 
et al 1997). 
The role of BRCA2 to cause the disease has been shown in a Hungarian study. 
BRCA2 germ-line mutations were detected in 6 of 18 male breast cancer patients 
(Csokay et al, 1999)，indicating that male breast cancer in that population has a strong 
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inherited component. 
In population based studies, approximately 3.3% of United States women with 
breast cancer have been shown to carry a pathogenic germline mutation in BRCAl 
(Newman et al, 1998). Mutations are more common in women with early onset breast 
cancer, being found in 6% of women diagnosed with breast cancer at or before the age 
of 35 years (Malone et al, 2000) (Peto et al, 1999). Mutations were also found in 12% 
of women diagnosed before the age of 45 years who had a first-degree relative with 
breast cancer (Malone et al, 2000) (Malone et al, 1998). 
Besides, pathways involving androgen signaling may modify BRCA1 -associated 
risk for breast cancer. CAG repeat length polymorphism found in exon 1 of the 
androgen receptor gene {AR-CAG) on age at diagnosis of breast cancer in known 
BRCAl mutation carriers has been studied by Rebbeck et al (Rebbeck et al, 1999). By 
comparing AR-CAG repeat lengths in affected and unaffected women with germline 
BRCAl mutations, women of at least one androgen-receptor allele with 28 or more 
CAG repeats, have a significantly increased risk for breast cancer. For those who 
carried an AR-CAG allele with 30 or more repeats, the mean age is 6.3 years earlier than 
that of those who do not carry at least one such allele. The function of the androgen 
receptor gene is a ligand-dependent transcriptional activator in response to androgens 
and has thought to be involved in breast tumor growth and progression (Zhu et al, 1997) 
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(Birrell et al, 1998). 
Ataxia-telangiectasia (AT) is a complex, autosomal recessive disorder 
characterized by cerebellar ataxia, oculocutaneous telangiectasia, radiation 
hypersensitivity and predisposition to cancer. AT patients are homozygous for 
germline mutation in the ATM gene (Wright et al, 1996). They have 60-180 folds of 
risk to develop cancers including non-Hodgkins lymphoma, breast and ovarian cancer 
(Morrell et al, 1986). The impact of ATM gene on heterozygotes has been speculated 
to play a role on breast cancer development. However, this issue is still controversial 
among different study groups. Relative risks of breast cancer ranging from 1.5 to 9 
has been reported on unaffected family members of AT patients (Swift et al, 1987) 
(Swift et al, 1991) (Easton，1994) (Inskip et al, 1999) (Janin et al, 1999). On the other 
hand, no increase prevalence of ATM mutations was found in 100 breast cancer patients 
with a family history (Chen et al, 1998), and in 100 breast cancer cases under the age of 
40 (Izatt et al, 1999). 
6 
B. Hormonal 
The development of the female breast is highly dependent on the availability and 
action of steroid hormones released by the gonads. Steroid hormones regulate the 
expression of numerous growth factors that act locally, mediating growth and 
differentiation signals. Reproductive hormones may increase breast cancer risk by 
affecting cell proliferation, DNA damage and promotion of cancer growth (Colditz, 
1998). 
Steroid hormones, including estrogens, androgens, and progestins, have been 
implicated in the pathogenesis and progression of breast cancer. Several factors alter 
exposure to endogenous hormones, such as age at menarche, age at first pregnancy, 
number of pregnancies, and age at menopause, have influences on breast cancer risks 
(Kelsey et al 1993). 
A direct effect of steroid hormones is that women who have bilateral 
oophorectomy at an early age (<40 years old) are at markedly reduced risks of 
subsequently developing breast cancer. The earlier oophorectomy is done, the greater 
the risk reduction (Hulka & Stark, 1995). 
Pregnancy has a complex relation with breast cancer, as risk is initially increased 
for a period of one to two decades (probably due to hormonal stimulation), but lifetime 
incidence is ultimately reduced (Lambe et al, 1994) (Rosner et al, 1994). Women who 
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undergo an early first full-term pregnancy (<30 years old) have a significant reduce 
breast cancer lifetime risk. This may be due to a complete differentiation of the 
glandular epithelium resulting in less proliferation (Russo et al, 1993). In contrast, 
women who undergo their first flill-term pregnancy after the age of 30-35 years appear 
to have a higher risk than that of nulliparous women. 
The impact of oral contraceptives and hormone replacement therapy on breast 
cancer remains controversial. Recent use of oral contraceptives may slightly increase 
the risk of breast cancer. Interestingly, this risk disappears and comparative to women 
who have never used the pill after 10 years or more from cessation (Collaborative 
Group on Hormonal Factors in Breast Cancer, 1996). 
Recent use of estrogen replacement therapy for more than 5 years also has been 
reported to increase breast cancer risk slightly. The higher risk is associated with 
longer use. Similar to the use of oral contraceptives, this effect seems to varnish 5 to 
10 years after the therapy is terminated (Collaborative Group on Hormonal Factors in 
Breast Cancer, 1997). 
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C. Environmental 
Studies of migrants have implicated that breast cancer is not exclusively due to 
genetic factors. Women who live in low-risk areas do not increase their risk after 
migrating to high-risk countries. It is the second and third generations, begins to 
experience rates of breast cancer incidence approaching those of the host country (WHO, 
1997). This strongly implicates that common environmental factors may be 
responsible for the disease, 
i. Diet 
Dietary factors are widely believed to play an important role in many cancers, 
including breast cancer. It is believed that high-fat, low-fiber, high-energy food, 
especially if consumed early in life, may increase the cancer risk. 
Vitamin A and carotenoids are considered anticarcinogenic. Fresh fruits and 
vegetables seem to confer protection (Trichopoulou et al, 1995). Heterocyclic amines, 
consumed with charbroiled food, have carcinogenic potential (Sugimura et al, 1994). 
Dietary fat may influence breast cancer risk by influencing endogenous hormone 
levels. Lower circulating concentrations of estrogen and progesterone has been 
mentioned with lower dietary fat intake (Boyd et al, 1998) (Wu et al, 1999). It has 
been suggested that the type and amount of fat in the diet is related to postmenopausal 
breast cancer (Wynder et al, 1997). 
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Soya consumption may in part account for geographical variation in breast cancer 
incidence. Plant estrogens found in soy products such as tofu have been suggested to 
confer protection against breast cancer in Asian populations (Messina & Bames，1991). 
This may be due to the weak estrogenic isoflavones in soya is effective in reducing 
circulating levels of ovarian hormones in premenopausal women without apparent effect 
on the levels of gonadotropins (Lu et al, 2000). 
ii. Radiation 
The association between exposure to ionizing radiation and breast cancer indicates 
that the mammary gland is susceptible to tumor initiation by DNA-damaging agents. 
It is a function of age at the time of exposure. 
Radiation exposure is evidently a risk factor, with significant increases in breast 
cancer observed among atomic bomb survivors. Studies of survivors from Hiroshima 
and Nagasaki indicate that the greatest increase in breast cancer risk occurred in women 
who were under 10 years old at the time of exposure (Tokunga et al, 1994). 
Breast cancer risk is also increased in women who received mantle radiation for 
Hodgkin disease as children (Bhatis et al, 1996). In addition, significant higher risks 
of breast cancer have been observed in women who underwent repeated fluoroscopy in 
the treatment of tuberculosis during adolescence as compared to that exposed at later 
ages (Boice & Monson，1977) (Miller et al, 1989) 
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Exposure to low dose of radiation at young age may play in concert with ATM 
mutation to increase the breast cancer risk. Broeks et al has reported an increased rate 
of ATM mutations in 82 patients diagnosed with breast cancer before the age of 45, in 
which 40% had contralateral disease and all of whom had been exposed to low dose 
radiation at a young age (Broeks et al, 2000). 
Hi. Physical Activity 
Current evidence suggests a reduced breast cancer risk is associated with physical 
activity. Physical activity is hypothesized to reduce the risk by altering the normal 
cycle of ovulation and menses during the reproductive years and in part by a body size 
reduction during the postmenopausal years (Gammon et al, 1998). The protective 
effects of physical activity are suggested to be greatest among women who are lean, 
who have carried children to term, and premenopausal (Friedenreich et al, 1998). 
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3. Histopathology 
Breast carcinoma arises from the epithelium of the mammary gland, which 
includes the milk-producing lobules and the ducts that carry milk to the nipple. 
Malignant transformation of the stromal, vascular, or adipose components of the breast 
is not included in this definition and is extremely rare. 
According to the information given by the World Health Organization (WHO, 
1982.)，the breast tumor histological types can be classified into: 
A. Noninvasive 
la. Intraductal carcinoma 
lb. Intraductal carcinoma with Paget's disease 
2. Lobular carcinoma in situ 
B. Invasive (infiltrating) 
1 a. Invasive ductal carcinoma — not otherwise specified (NOS) 
lb. Invasive ductal carcinoma with Paget，s disease 
2. Invasive lobular carcinoma 
3. Medullary carcinoma 
4. Colloid carcinoma (mucinous carcinoma) 
5. Tubular carcinoma 
6. Adenoid cystic carcinoma 
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7. Apocrine carcinoma 
8. Invasive papillary carcinoma 
Amongst different types of breast neoplasms, ductal carcinoma is the most 
common type worldwide. Locally, ductal carcinoma of the breast accounts for around 
80% of all breast cancer subtypes (Hong Kong Cancer Registry, 1998-1999.). 
4. Clonality Nature of Cancer 
It is now generally believed that multiple genetic mutations are present in human 
tumors (Renan, 1993). Tumorigenesis is thus believed to be a multiple step process 
involving the activation of oncogenes and inactivation of tumor suppression genes 
(Vogelstein & Kinzler，1993). Such process is thought to occur through clonal 
evolution (Norwell, 1976). The ancestral cell inherited or acquired a cancer-promoting 
mutation and passed to its progeny and all future generations. Once sufficient genetic 
alterations were accumulated in a single progeny cell, it became a cancer cell, which 
had acquired the ability to replicate uncontrollably. 
The molecular progression model of colorectal cancer established by Fearon and 
Vogelstein in 1991 (Fearon & Vogelstein，1991) is now serving as a paradigm for the 
development of molecular progression models for many other solid neoplasms 
(Sidransky, 1995). If a cancer developed in a clonal fashion, mutations arising in an 
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early stage of tumor development would be expected to be present in later stages, and 
each successive stage would be marked by additional mutations. 
In the colorectal cancer progression model, Fearon and Vogelstein clearly 
demonstrated that activation of the K-ras oncogene and inactivation of adenomatous 
polyposis coli (APQ tumor suppressor gene occurred early in the development of 
colorectal adenoma. This was followed by loss of chromosome 17p and 18q (probably 
the p53 gene and the DCC gene, respectively) to become progressive and invasive 
(Fearon & Vogelstein，1991). 
5. Knudson "two-hit" Hypothesis on Cancer Development 
Knudson has proposed in 1971，on the basis of population incidence curves, that 
two rate-limiting genetic events, or "hits" are sufficient to lead to a clinically manifest 
retinoblastoma (Knudson, 1971). In inherited cases, the first hit is transmitted through 
the germ line, followed by loss of function of the wild type allele as the second hit. In 
the sporadic form of the disease that is not inherited, both hits are acquired at the 
somatic level. The stochastic of mutation rates and tumor growth dynamic have 
explained why inherited cases usually occur bilaterally and at earlier ages than the 
sporadic form of the disease. 
It has been shown that the second hit in inherited retinoblastoma is frequently due 
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to deletion, mitotic recombination or non-disjunctional chromosome loss (Cavenee et al, 
1983). All these events lead to LOH over large regions of the chromosome, but 
always include the retinoblastoma gene locus. Mutation analysis has shown that the 
allele retained in the tumor of hereditary patients is the inherited mutated copy of 
retinoblastoma gene. In sporadic retinoblastoma, acquired mutations and LOH are 
found (Dunn et al, 1988). Most of the known TSGs to date display these genetic 
features and are associated with rare inherited cancer syndromes. The Knudson 
"two-hit" hypothesis has thus provided the rationale for studies that aim to identify 
TSGs by mapping regions of allelic loss. 
6. Molecular Genetic Studies of Breast Cancer 
Invasive breast cancers are considered to arise from premalignant breast lesions. 
These premalignant lesions include ductal hyperplasia, atypical ductal hyperplasia, 
atypical lobular hyperplasia, ductal carcinoma in situ, and lobular carcinoma in situ. 
The pathogenesis of breast cancer, like most other cancers, is believed to be the 
results of accumulation of multiple genetic alterations leading to oncogene 
overexpression and tumor suppressor loss. 
Although enormous studies have focus on the breast cancer biology, a limited 
number of genes have been found mutated. On the other hand, a large number of 
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chromosomal regions with unidentified genes have been reported. 
In the review paper of Ingvarsson published in 1999，some detected genetic 
abnormalities in breast cancers are mentioned (Ingvarsson, 1999). They are 
amplification of oncogenes {MYC, ERBB2 and CCNDl), mutations of the tumor 
suppression genes {TP53 and CDH1\ and loss of heterozygosity at chromosomes 1, 3p, 
6q, 7q, 8p, 9p, lOq, 11, 13q, 16q, 17，18q, 22q and X. 
A. Loss of Heterozygosity 
Loss of heterozygozity (LOH) is a common molecular genetic alteration observed 
in human cancers. It results from the loss or amplification of one of the parental 
alleles present in one's normal cell. LOH study is the most frequently use molecular 
strategy in cancer research to delineate tumor suppressor loci. It is a polymerase chain 
reaction (PCR) technique, which utilizes polymorphic microsatellite markers for 
investigation of allelic imbalance (Al). Advantages of this technique include rapid, 
small amount of DNA required, and support high-resolution allelotyping provided that 
large panel of microsatellite markers is available. However, the technique has the 
problems of distinguishing between deletions and amplifications, and interpretation of 
results requires expertise to avoid false positive or false negative results. 
LOH studies on breast cancers are plentiful. Every chromosome in the human 
genome has been investigated. Numerous investigators have attempted to identify 
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tumor suppressor genes (TSGs) in this cancer. Although many altered chromosomal 
regions of potential tumor suppressor action have been identified, none has actually 
been found (Tomlinson et al, 2002). 
To cope with the enormous data on breast cancer by different investigators, 
Osborne and Hamshere have constructed a framework map that integrates data from 
143 studies on the LOH or Al in the disease (Osborne & Hamshere, 2000). 
Full details of these LOH maps can be found at the web site 
(http://www.nottingham.ac.uk/~pdzmgh/loh/). 
By combining results from the data, Osborne and Hamshere (Osborne & Hamshere， 
2000) have identified minimum commonly deleted regions (CDRs) on each 
chromosome. In addition, they have highlighted 26 chromosomal regions on 16 
different chromosomes and corresponding candidate genes. These 26 chromosomal 
regions are present in table I-l. 
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Commonly Deletion Region Candidate Gene(s) 





6q22.1-23.1 MYB and ROSl 
6q25.2-27 hZAC and ESR-1 
7q31.3-31.31 CAV-I 
8p22-21.3 W 3 
MYC 
^ “ CDKN2A and CDKN2B 
10q23.31-23.33 SNCG and PTEN 
T l ^ ‘ ^ ST5, TSG�01 and HRAS 





16ql 1.2-22.1 CDHl 
16q22.3-24.3 CDHB 
17pl3.3 “ BCPR 
17pl3.1 “ 
17q21.23 “ BRCAl 
18q21.1-21.3 'dCC 
22ql2.3 RRP22 and NF2 
22ql3.1 Sfl3 
Table I-l: Commonly deletion regions harboring candidate genes in breast cancer. 
(Osborne & Hamshere，2000) 
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B. Comparative Genomic Hybridization 
Comparative genomic hybridization (CGH) is a newly developed molecular 
cytogenetic technique, which acts as a complement of the conventional cytogenetic 
analysis in analyzing the overall chromosomal abnormalities of solid tumors 
(Kallioniemi et al, 1992). CGH can detects DNA sequence copy number changes of 
the whole tumor genome in one single experiment, without prior knowledge of the 
aberrations of the investigated samples. It is useful for detecting patterns of 
chromosomal gains and losses of cancers. 
Roylance et al have performed CGH technique on 40 grade I, and 50 grade III 
invasive ductal breast carcinomas (Roylance et al, 1999). They have found that the 
most common regions of gain are chromosomes Iq, 8q, 16p, 17q, and 20q on the 50 
grade III tumors. The most common regions of loss are chromosomes Ip，8p, l lq, 13q 
and 18q. 
Similar common altered chromosomal regions has been reported by another 
research group (Kuukasjarvi et al, 1997)，studying 29 primary breast carcinomas and 
their paired asynchronous metastases by CGH and fluorescence in situ hybridization 
(FISH). These chromosomal defects are also common in 38 breast cancer cell lines 
examined (Forozan et al, 2000). 
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C. Epigenetic Changes 
Epigenetic change is defined as modifications of the genome, heritable during cell 
division, that do not involve a change in the DNA sequence (Feinberg, 2001). One 
common thread to most epigenetic phenomena is DNA methylation, a covalent 
modification of the C5 position of cytosine. The most widely studied epigenetic 
abnormality in tumorigenesis is the silencing of gene transcription associated with gains 
of DNA methylation in normally unmethylated gene promoter regions (Baylin & 
Herman, 2000) (Jones & Laird，1999). 
Promoter hypermethylation is an alternative mechanism of transcriptional 
repression of TSGs in human (Baylin et al, 1998). Methylation is the main epigenetic 
modification in humans, and changes in patterns of methylation play an important role 
in tumorigenesis. To date, a vast number of normally unmethylated CpG islands 
located in the promoter regions of many tumor suppressor and DNA repair genes have 
been mentioned in different cancer cell lines and primary tumors (Esteller et al, 2001) 
(Yang X，2001)，with their loss of expression due to aberrant hypermethylation. 
Examples of affected genes relating to promoter hypermethylation in breast cancers are 
\4-3-3c7, RAR/32, ESR, PR, pl6’ CHDL and BRCAL (Yang X et al, 2001). Thus 
promoter hypermethylation is now considered as one of the "hits" in cancer biology 
(Baylin et al, 1998)，regarding to Knudson's famous "two hit" hypothesis (Knudson, 
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1971). 
7. Genetic Changes in Breast Cancer 
A. Chromosome 1 
14-3-3(7 Gene 
The 1^-i-Jcrgene, also called stratifm or HME-1, is located on chromosome lp35. 
It is a member of a gene family responsible for instituting the G2 cell cycle checkpoint 
in response to DNA damage in human (Chan et al, 1999). Normally expression of 
gene product is induced in response to DNA damage, and it causes cells to arrest in G2. 
However, cr protein expression was found to be down-regulated in a significant 
fraction of primary bladder, colon and breast tumor (Celis et al, 1999). Despite the 
putative tumor suppressor activity of 14-3-3a, mutations or loss of the gene in human 
cancers have not been reported. 
Recently Ferguson et al (Ferguson et al, 2000) has reported that 14-3-3 cr gene 
expression was greatly reduced in breast cancer cells comparing to normal breast 
epithelia cells by serial analysis of gene expression (SAGE) analysis. Results have 
been verified by Northern blot analysis, in which mRNA cannot be detected in 45 of 48 
primary breast carcinomas. Interestingly, genetic alterations at 14-3-3 <j such as LOH 
is detected in only 1 of 20 informative cases and no mutations are found in 34 cases. 
On the other hand, hypermethylation of CpG islands is detected in 75 of 82 (91%) 
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cases. 
Therefore it is possible that loss of 14-3-3 a expression contributed to malignant 
transformation by impairing the G2 cell cycle checkpoint function, thus allowing an 
accumulation of genetic defects in breast carcinogenesis (Ferguson et al, 2000). 
B. Chromosome 3 
LOH on the short arm of chromosome 3 is a frequently observed genetic alteration 
in a variety of human epithelia tumors, including lung (Wistuba et al, 2000), cervix 
(Acevedo et al, 2002), head and neck (Hogg et al, 2002), and nasopharygnx (Lo et al, 
2001). Allelic loss on chromosome 3p is also high in breast lesions, up to 87% in 
primary breast cancers, 92% in ductal carcinoma in situ, 29% in apocrine metaplasia, 
and 28% in usual epithelial hyperplasia of the breast (Maitra et al, 2001). The various 
affected regions are (Maitra et al, 2001) 3p21.1 (69%), 3p22-24 (61%), 3p21.2-21.3 
(58%), 3p25 (48%), 3pl4.2 (45%), 3pl4.3 (41%)，and 3pl2 (35%). 
Several candidate genes resided on chromosome 3p have been analyzed on breast 
cancer pathogenesis, including MR阳’ FHIT, RASSFIA, and TRJ3L 
i. Retinoic Acid Receptor P2 Gene 
Retinoic Acid Receptor p2 (RARj32) gene is a candidate tumor suppressor gene, 
located on chromosome 3p24. It appears to play an important role in limiting the 
growth of certain malignant tumor types, including lung carcinoma, squamous cell 
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carcinoma of the head and neck, and breast (Picard et al, 1999) (Xu et al, 1999) (Xu et 
al, 1997). The loss of this regulatory activity is associated with tumorigenesis. 
DNA methylation of the RARp2 promoter is believed to be one of the factors 
linked to RARj32 down-regulation in breast cancer (Widschwendter et al, 2000). 
RAR/32 promoter hypermethylation has been demonstrated by both Southern and 
methylation-specific PCR analyses in several RAR/32-nQg2iti\Q human breast cancer cell 
lines and about one-third of unselected primary breast cancer specimens (Sirchia et al, 
2000). It was not observed in normal breast tissues. 
Yang et al (Yang Q et al, 2001) have applied LOH and methylation-specific PCR 
analyses to investigate RARp2 in breast cancer cell lines and primary breast cancers. 
They have demonstrated that biallelic inactivation via epigenetic changes of both 
maternal and paternal alleles, or epigenetic modification of one allele combined with 
genetic loss of the remaining allele, can completely suppress RARJ32 expression in 
breast cancer. In that study, seven breast cancer samples with normal RARj32 
expression but LOH at 3p24 locus was found. This suggests that RARp2 can be 
expressed in a monoallelic fashion. It also implies that epigenetic gene inactivation is 
a highly efficient mechanism of silencing RARP2 gene expression. 
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ii. Fragile Histidine Triad Gene 
The Fragile Histidine Triad {FHIT) gene resided on chromosome 3pl4.2 is a 
candidate TSG in breast cancers. It is more than 1 Mb in size and encodes a 1.1 kb 
cDNA with 10 small exons. Exon 5 is the first protein encoding exon, and it is flanked 
in intron 4 and intron 5 by the most common fragile site in the human genome, FRA3B 
(Ohta et al, 1996). 
FHIT transcripts of abnormal size, including deletions of exons and insertions, 
were found in breast cancers, whereas point mutations were rare (Negrini et al, 1996) 
(Ahmadian et al, 1997). Exon 8, which contains the histidine triad domain, is most 
frequently absent, suggesting this exon may contains an essential function that is lost in 
the tumorigenesis (Negrini et al, 1996). 
The 5' CpG island methylation of the FHIT gene is correlated with loss of gene 
expression in breast cancers. FHIT methylation has been detected in 31% of primary 
breast cancers, and 86% of breast cancer cell lines (Zochbauer-Muller et al, 2001). 
Such methylation is significantly correlated with loss of FHIT expression in breast 
tumors demonstrated by immunostaining (Zochbauer-Muller et al, 2001). 
Silencing of the FHIT gene by promoter hypermethylation in breast cancer may be 
further enhanced in companion with LOH. In a study of the role of LOH and 
hypermethylation for FHIT inactivation in Japanese breast carcinomas, 46 sporadic 
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invasive ductal carcinomas have been tested. LOH has been detected in 8 of 40 (20%) 
informative tumors, and hypermethylation has been detected in 22 of 46 (48%) cases. 
Complete loss of FHIT protein expression is observed in all seven tumors harboring 
both LOH and hypermethylation (Yang et al, 2002). 
Hi. Ras Association Domain Family 1A Gene 
The human Ras association domain family 1A gene (RASSFIA) gene is resided on 
chromosome 3p21.3. The RASSFl protein has 3 transcripts, A, B, and C. The 
transcript A is missing in small cell lung cancer cell lines and several other cell lines 
(Dammann et al, 2000). Loss of expression has been reported to correlate with 
methylation of the CpG island promoter sequence of RASSFIA. 
Agathanggelou et al (Agathanggelou et al’ 2001) have reported that RASSFIA 
promoter region CpG island methylation occurred in 9% primary breast cancer, and in 
80% breast cancer cell lines. In view of the low frequency of RASSFIA methylation in 
primary breast cancers, they proceed to mutation analysis of RASSFIA, RASSFIB and 
RASSFlC in 36 breast carcinomas and four breast tumor lines by SSCP analysis. No 
mutations have been detected, but six single nucleotide polymorphisms are identified. 
The methylation frequency of RASSFIA promoter region is not the same in another 
article published in the same year. Dammann et al (Dammann et al, 2001) have found 
28 of the 45 primary breast cancers to be methylated. No somatic mutations are found 
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in the 17 samples that are not methylated. Methylation is also detected in 7.5% of 
normal samples but at a lower degree than the corresponding tumor samples. 
Interestingly, a constant methylation frequency of RASSFIA is detected in all of the 
different grades of the breast carcinomas. Thus, methylation of RASSFIA may be an 
early event during breast cancer pathogenesis, 
iv. Thyroid Hormone Receptor pi Gene 
Thyroid hormone receptor pi {TRpl) gene is resided on chromosome 3p24.3. 
Thyroid hormone receptors are ligand-mediated transcription factors, which form 
complexes with other nuclear receptors and multiple effector proteins to regulate growth, 
differentiation, and development (Chen & Evans, 1995). 
A variable degree of TRpi promoter hypermethylation has been shown in all 
eleven cases of ductal breast carcinomas by Li et al (Li et al, 2002). However, a high 
frequency of aberrant promoter hypermethylation is also detected in nonmalignant 
tissue, which is peripheral to carcinoma in 4 of 11 cases in the same study. The 
possible role of TRpl gene in breast tumorigenesis is still questionable. 
26 
C. Chromosome 5 
Adenomatous Polyposis Coli Gene 
Adenomatous polyposis coli {APC) gene is resided on chromosome 5q21. It is a 
TSG and mutations of it are responsible for both familial and sporadic colorectal 
cancers (Groden et al, 1991) (Nishisho et al, 1991). It is an important component of 
the Wnt signaling pathway, which binds to and inactivates p-catenin. Biallelic 
inactivation of the gene in familial adenomatous polyposis and most sporadic colorectal 
tumors promotes tumorigenesis (Polakis, 1997). 
Previously, the APC gene mutation on breast cancers was considered rare，in 
contrast to the frequent allele loss at chromosome 5q21 on the disease (Thompson et al, 
1993). This may be due to the large size of the APC gene, rendering the conventional 
mutation analysis labor-intensive and less sensitive. 
Furuuchi et al (Furuuchi et al, 2000) have developed a sensitive yeast-based assay 
for screening almost the entire coding region of the APC gene. Somatic APC gene 
mutations are detected in 18% of 70 sporadic breast cancers. The majority of the 
mutations are found in solid tubular carcinomas (7 of 25), papillotubular carcinomas (5 
of 27), and scirrhous-type tumors (1 of 14). They have shown that most mutations 
detected are scattered on the entire APC coding region and only 27% are located in the 
mutation cluster region. This indicates that the concept of a mutation cluster region of 
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the APC in colorectal cancers is not applicable to breast cancers (Furuuchi et al, 2000). 
Moreover, mutations are significantly more frequent in higher, advanced stages, 
suggesting that the APC mutations are associated with tumor progression in breast 
cancers. 
Epigenetic change of the APC gene has also been studied. It has been shown that 
promoter lA of the APC gene is hypermethylated in 37 of 77 (44%) breast cancer 
tumors and cell lines, and LOH is detected in 63% of breast cancer cell lines (Virmani et 
al，2001). The frequency of methylation in breast cancers increases with tumor stage 
and size, suggesting that methylation may be associated with poor prognosis. 
D. Chromosome 6 
Estrogen Receptor Gene 
Steroid hormones, particularly estrogen, have long been speculated to play a part in 
breast tumorigenesis (Colditz, 1998). ThelVp-estradiol stimulates the growth of 
certain breast cancers via functional estrogen receptor is well recognized, and endocrine 
therapy is an established and important part of breast cancer management (Ruiz-Cabello 
etal, 1995) (Davidson, 2000). 
The presence of estrogen receptor in breast cancers is a predictor for response to 
hormone therapy. In fact, estrogen receptor is absent in about one-third of breast 
cancers at the time of diagnosis, and a proportion of estrogen receptor positive breast 
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cancers lose it during tumor progression (Hortobagyi, 1998). 
The estrogen receptor (ESR) gene is resided on chromosome 6q25.1. Genetic 
alterations, such as homozygous deletion, LOH or gene mutation of ESR have not been 
reported to play a major role in loss of ESR expression (Yang X et al, 2001). 
Besides, epigenetic alterations have been reported to play a role in inactivation of 
the gene (Ottaviano et al’ 1994) (Nass et al, 2000). Increasing frequencies of ESR 
methylation have been shown in 12 of 35 (34%) on ductal carcinoma in situ, 25 of 48 
(52%) on invasive ductal carcinoma, and 17 of 28 (61%) on locally advanced and 
metastatic breast carcinoma (Nass et al, 2000). 
E. Chromosome 9 
Frequent LOH and homozygous deletions of chromosome 9p21-22 in 38 to 58% of 
breast cancers have been reported in deletion mapping studies with highly informative 
microsatellite markers (Eiriksdottir et al, 1995) (Brenner & Aldaz，1995) (An et al, 
1996) (Marsh & Varley，1998). Thepl6 gene is the most well known TSG resided on 
this chromosome region. 
pi 6 Gene 
The pl6 gene is resided on chromosome 9p21. It encodes a cyclin-dependent 
kinase inhibitor��?/6'"^� that regulates the transition from Gl- to S-phase via its effect 
on Rb phosphorylation (Liggett & Sidransky，1998). 
29 
Loss of pl6 gene resulting from homozygous deletion, methylation or point 
mutation is a common event of many cancers. Germline mutations in pl6 have been 
associated with familial cancers including melanoma, pancreatic cancer, and head and 
neck cancer (Yarbrough et al, 1996). However, the incidence of homozygous deletion 
and missense mutation is low in breast cancer (Ruas & Peters, 1998). 
On the other hand, methylation of the 5' promoter and exon 1 regions is observed 
in both human breast cancer cell lines and 20-30% of primary breast cancers (Herman et 
al, 1995) (Woodcock et al’ 1999). The methylation phenotype is associated with loss 
of expression at both mRNA and protein levels, but it does not correlate with overall or 
disease-free survival (Hui et al, 2000). 
F. Chromosome 13 
On the long arm of chromosome 13 lies two known TSGs, namely the 
retinoblastoma gene (RBJ) and the BRCA2 gene. LOH study on chromosome 13 has 
detected allelic imbalance (Al) in 52-63% of sporadic breast tumors (Hamann et al, 
1996)，in which nine cases with Al only occurred in the BRCA2 region but not at RBI, 
and six cases vice versa. This suggests that both BRCA2 and RBI may be distinct 
target loci on chromosome 13 in sporadic breast cancer. 
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i. BRCA2 Gene 
The BRCA2 gene is located within a 6 cM interval on chromosome 13ql2-13. It 
is composed of 27 exons, of which the first is non-coding, and encodes a protein of 
3,418 amino acid residues (Tavtigian et al, 1996). It has been shown that BRCA2 
expression is coordinately regulated with BRCAl expression during proliferation and 
differentiation in mammary epithelial cells, suggesting that both genes may act in the 
same pathway (Rajan et al, 1996). Similarly to BRCAl, BRCA2 interacts with the 
DNA-repair protein Rad51, providing support to the proposal that these proteins may be 
essential cofactors in the RadSl-mediated DNA repair of double-strand breaks (Sharan 
et al, 1997). 
The BRCA2 gene is one of the known breast cancer susceptibility genes. 
Germline mutations in the BRCA2 gene have been identified in families prone to breast 
cancer (Tavtigian et al, 1996). It has been reported that LOH on chromosome 13q 
occurred in approximately 90% breast and other cancers from individuals in families 
linked to BRCA2 (Collins et al, 1995) (Gudmundsson et al’ 1995). Moreover, 
frequently is the loss of the unaffected wildtype allele in the tumors, the pattern 
expected of a TSG 
On the other hand, the story is different on sporadic breast cancers. LOH on 
chromosome 13ql2-13 is detected in 30-40% sporadic breast cancers (Cleton-Jansen et 
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al, 1995). However, mutations in the BRCA2 gene are rare at somatic level (Teng et al, 
1996) (Miki et al, 1996). It is not clear if the BRCA2 gene is inactivated by other 
mechanisms, or the observed LOH on chromosome 13q is directed at other targets in 
sporadic breast cancers, 
ii. Retinoblastoma Gene 
The retinoblastoma gene {RBI) is resided on chromosome 13ql4 and is frequently 
deleted in retinoblastoma (Friend et al, 1986). It has a complex organization with 27 
exons, spanning greater than 200 kb of DNA, and an RNA transcript of about 4.7 kb 
expression. 
The RBI gene product (Rb) is a nuclear protein. It is inactivated when mutated, 
or by phosphorylation, which is catalyzed by one or more cyclin-dependent 
protein/kinases. A large number of cellular growth-regulatory proteins such as 
members of the MYC and cyclin families, and the transcription factor E2F-1 bind the Rb. 
The function of RBI appears to restrict cellular entry into the S phase of the cell cycle. 
It is thought that Rb binds E2F-1 to form a dimeric transcription factor capable of 
regulating genes involved in Gi-S progression (Fung & T'Ang，1991) (Chellappan et al, 
1991). 
The RBI gene is mutated in approximately 20% of breast cancers (Fung & T，Ang， 
1991). Loss of Rb expression ranges from 26 to 44% of breast tumors by 
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immunohistochemical staining (Jares et al, 1997) (de Jong et al, 1998). RBI mRNA 
has also been quantified by reverse transcriptase-PCR in sporadic breast cancers. 
Underexpression of RBI is observed in 22% of 129 breast cancer cases, and is 
correlated with LOH at the RBI locus (Bieche & Lidereau，2000). Thus, it is likely 
that the RBI gene is a target gene on chromosome 13q related to the pathogenesis of 
breast cancer. 
G Chromosome 16 
E-cadherin Gene 
The E-cadherin (CDHl) gene is resided at chromosome 16q22.1. It encodes a 
cell-surface adhesion protein that is important in maintaining homophilic cell-cell 
adhesion in epithelial tissues (Ilyas & Tomlinson，1997). Loss of expression of CDHl 
is associated with poorly differentiated tumors and poorer prognosis in breast cancers 
(Siitonen et al’ 1996). 
Chromosome 16q22.1 locus is the LOH hotspot in sporadic breast cancers 
(Skimisdottir et al, 1995) (Cleton-Jansen et al, 2001). It is only the rare mucinous 
breast tumors showed no 16q LOH at all (Cleton-Jansen et al’ 2001). Interestingly 
CDHl has been found mutated in a large portion of lobular breast tumors (Berx et al, 
1995) (Berx et al, 1996), but no CDHl mutations have been detected in tumors in the 
breast of the ductal histological type. This is the clearest evidence of molecular 
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difference in the two histological types of breast cancer (Ingvarsson, 1999). 
Mutation analysis and LOH studies on lobular carcinoma in situ (LCIS) and 
adjacent invasive lobular carcinoma (ILC) further prove the tumor suppressor role of 
CDHl in lobular breast carcinogenesis (Vos et al, 1997). The same truncating 
mutations, and LOH of the wild type CDHl in the LCIS component and adjacent ILC 
are found, indicating that loss of CDHl function is an early event in lobular breast 
carcinogenesis. 
Although no CDHl mutation has been found in ductal breast lesions, the second 
"hit" of CDHl inactivation may be accomplished by epigenetic changes. In fact, 
hypermethylation of the CDHl CpG island has been reported in about 30% of ductal 
carcinomas in situ (DCIS), and significantly increased to 60% of metastatic lesions, 
suggesting a role of CDHl in breast cancer progression (Nass et al, 2000). 
H. Chromosome 17 
i. TP53 Gene 
The TP53 gene is resided on chromosome 17pl3.L It is the most extensive 
studied TSG. Exposure of cells to stress activates the p53 tumor suppressor protein. 
This activation is cardinal for the efficient response of cells to stress stimuli, such as 
DNA damage and hypoxia (Giaccia et al，1998). The response takes the form of 
growth arrest, senescence, or apoptosis (Asker et al, 1999). Loss of TP53 function, 
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either by mutations or by deregulation of regulatory proteins, is often detrimental, 
leading eventually to development of cancer (Levine, 1997). 
The most common mutations are missense mutations that result in conformational 
alteration and dysfunction of p53 protein (Ko et al, 1996). This mutant p53 protein is 
stable and accumulated to very high levels in the cell nuclei (Davidoff et al, 1991). 
Hence, immunohistochemical staining is a relatively easy and accurate surrogate 
approach for detecting p53 mutations. 
More than 50% of all cancers contain mutations in the TP53 gene (Hollstein et al, 
1991). In breast cancer, the frequency of TP53 mutation is varied among different 
populations. In most ethnic groups, 15-34% of breast cancer with TP53 mutations is 
noted, comparing to 56-71% in certain regions of Japan (Hartmann et al, 1997). 
The TP53 gene mutation may not correlate with LOH at the TP53 locus 
(Thompson et al, 1992) (Deng et al, 1994). LOH of the TP53 locus has been found in 
about 50% cases with no detectable mutations, whereas about 50% cases with TP53 
mutations showed no relevant LOH (Deng et al, 1994). This may suggest that breast 
cancers often have only one defective allele of the p53 gene. Furthermore, the 
spectrum of mutations in breast cancer differs from that of colon cancer or non-small 
cell lung cancer (Hollstein et al，1991)，strongly suggesting distinct origins among 
different tumor types (Deng et al, 1994). 
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ii. BRCAl Gene 
The BRCAl gene is a putative TSG resided on chromosome 17q21 and spans lOkb 
of genomic DNA, which encodes a protein of 220 kDa consisting of 1863 amino acids 
(Hall et al, 1990). BRCAl has the function to preserve genome integrity. It binds to 
the Rad50 and RadSl DNA repair proteins (Scully et al, 1997) (Zhong et al, 1999). It 
is suggested that BRCAl played roles in transcription-coupled repair (Gowen et al, 1998) 
and double-strand DNA break repair (Scully et al, 1999). The BRCAl related breast 
carcinomas contain two to three fold more chromosomal rearrangements than sporadic 
cases, supporting the role of BRCAl for DNA damage repair. 
In population based studies, approximately 3.3% of United States women with 
breast cancer have been shown to carry a pathogenic germline mutation in BRCAl 
(Newman et al, 1998). Surprisingly, in contrast to other TSGs, somatic mutations is 
rare, despite the high degree of LOH at the BRCAl locus in sporadic breast cancer 
(Merajver et al, 1995) (Rahman & Stratton，1998). 
Reduction in BRCAl mRNA levels in breast cancer compared to the normal 
mammary epithelium is suggestive of a role for BRCAl in sporadic breast cancer. 
Decreased BRCAl mRNA expression has been correlated with tumor progression 
(Thompson et al’ 1995) and distant metastasis (Seery et al’ 1999) of sporadic breast 
cancers. 
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Since BRCAl transcript and protein are absent or reduced, and somatic mutation is 
rare in sporadic breast cancer, DNA methylation is proposed as an alternative 
mechanism to inactivate BRCAL BRCAl promoter is methylated in 13% of 194 
unselected primary breast tumors (Esteller et al, 2000). Besides, BRCAl methylation 
are only observed in breast and ovary cancers but not in tumors of colon, liver or 
leukemia, supporting a tissue specific event for the process. 
In addition, aberrant BRCAl CpG island promoter is associated with decreased 
BRCAl mRNA in sporadic breast cancer cells and tumors (Rice et al, 1998) (Rice et al, 
2000)，as well as BRCAl protein loss in sporadic breast cancers (Niwa et al, 2000). 
Thus hypermethylation and allelic loss may play a role in BRCAl inactivation other 
than the rare event of somatic mutation in sporadic breast cancer. 
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CHAPTER II: MATERIALS AND METHODS 
I. PATIENTS AND SPECIMENS 
Twenty-six cases of breast cancers from local Chinese female populations with 
paired neoplastic and normal frozen blocks were retrieved from the frozen tissue bank at 
the Department of Anatomical and Cellular Pathology in Prince of Wales Hospital, the 
Chinese University of Hong Kong, Hong Kong Special Administrative Region. The 
specimens were collected from 1998 to 2001. All were subjected to allelotyping on 22 
autosomes with 382 fluorescent labeled microsatellite markers. 
Upon receive of the fresh mastectomy specimen from the operation theatre, one 
small piece of tumor tissue and one piece of normal breast parenchyma distant from the 
lesion were obtained from the on duty pathologist. Tissue blocks were separately snap 
frozen in liquid nitrogen and stored at -80°C, until retrieval for DNA extraction. The 
remaining specimen was fixed in 10% buffered formalin for surgical cutting, paraffin 
blocking and pathological diagnosis. 
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The twenty-six cases of primary female breast cancer were all classified as 
invasive ductal carcinoma of the breast, ranging from grade I to Grade III according to 
the Bloom and Richardson grading system, counting on the extent of tubule formation, 
pleomorphism, and mitoses. All twenty-six patients were local Chinese, with the age 
ranged from 34 to 85 years old. The mean age was 52 years old. The age of the patients 
and the tumor grade is shown on table II-1. 
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Sample Number Age Grade 
brI ^ in 
B ^ ^ in 
^ 79 n 
BR4 40 n 
B ^ 47 n 
BR6 34 n 
^ ^ n 
37 m 
BRIO ^ m 
BRii ^ n 
BR12 35 I 
BR14 36 i n 
BR15 ^ I 
BR16 ^ in 
BR17 49 n 
BR18 ^ m 
BR19 48 m 
BR21 35 m 
BR22 78 m 
BR23 45 i n 
BR24 S i n 
BR25 51 m 
BR27 52 m 
BR28 46 m 
BR29 46 n 
BR30 ^ i n 
Table II-1. Age and Tumor Grade of Breast Cancer Cases. 
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II. FROZEN SECTIONS AND MICRODISSECTION 
Serial frozen sections were cut in a cryostat microtome. The first and the last 
frozen sections were cut at 6 micrometers, stained with haematoxylin and eosin (H&E) 
for histological examination, to counter-check with the correlating paraffin section. 
In order to obtain good quality and sufficient DNA for the genome wide 
allelotyping, 20 to 40 serial thick frozen sections of 25 micrometers in thickness on each 
frozen block were cut. The cut thick sections were mounted on sterilize plain glasses, 
briefly fixed with 70% ethanol, and lightly stained with Mayer's haematoxylin. 
The target components for allelotyping were confirmed by pathologists before 
microdissection. Manual microdissection was performed on haematoxylin stained 
thick frozen sections, to enrich the pure population of desired tumor and normal cell 
components separately for comparisons. It was done by a sterile fine needle under an 
inverted microscope. More than 5 X 10^ cells were microdissected from each sample 
frozen block. The microdissected cells were estimated to be over 80% of cancer cells 
from the tumor blocks, and 100% of normal components from the normal tissue blocks. 
Figure II-1 and figure II-2 are shown to illustrate the breast cancer sample BR8 before 
and after the manual microdissection. Cancer cells were microdissected and subjected 
for DNA extraction. Corresponding normal DNA was obtained from a separate normal 
tissue block far away from the cancer location. 
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Figure II-1: Breast cancer sample BR8 before microdissection. 
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a f c a III � Figure II-2: Breast cancer sample BR8 after microdissection. The surrounding normal components were e ove . 
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III. DNA EXTRACTION 
High molecular weight DNA was extracted from microdissected tissues by 
conventional proteinase K and phenol-chloroform method (Maniatas et al, 1989). 
Microdissected tissues were firstly digested overnight in saline Tris-EDTA (STE) 
solution containing 0.5% SDS and 0.2 mg/ml proteinase K (Sigma, St. Louis, MO) at 
55°C with agitation. After overnight digestion, phenol/chloroform extraction was 
performed to denature and remove the protein content. In brief, the solution was 
mixed with phenol/chloroform/isoamylalcohol (25:24:1 in volume) solution (Ameresco, 
Solon, Ohio) for 10 minutes with shaking. It was then left at 4®C for 20 minutes and 
centrifuged at 400 rpm for 20 minutes. The upper aqueous layer was collected, 
precipitated with one in tenth volume 3M sodium acetate (pH5.2) and 2.2 volumes cold 
absolute ethanol, then kept at -20°C for one hour to assist DNA precipitation. The 
chilled sample was then centrifuged at 4000 rpm for 20 minutes. The supernatant was 
drained with the DNA pellet left at the bottom. The DNA pellet was washed twice 
with cold 70% ethanol, dried and dissolved in sterile distilled water at 4 � C overnight. 
The dissolved DNA solution was aliquated and stored at 20°C for allelotyping study. 
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IV. ALLELOTYPING 
A total of 382 fluorescent dye labeled microsatellite markers were applied on 
paired normal and breast cancer DNA. The microsatellite markers were spanning on 
the 22 autosomes, purchased from Applied Biosystems (Foster City, CA). All these 
microsatellite primer pairs were from the ABI PRISM Linkage Mapping Set MD-2 
(http://www.pebio.com/ab/applv/dr/Imsv2/). The average interval of the loci is 10 cM. 
All markers were organized into 27 panels. Each panel contained between 10-20 
fluorescent dye labeled primer pairs. The generated PGR products from each panel 
could be pooled and detected in a single gel lane because the primers were designed to 
produce products over a broad molecular weight range. Overlapping alleles were 
distinguished by labeling with three different fluorescent dyes, (FAM), (HEX), (NED), 
which displayed on the ABI PRISM 377 analyzer as blue, green and yellow 
respectively. 
1. Polymerase Chain Reaction 
Each sample was amplified according to the manufacturer's recommendation. 
Multiplex polymerase chain reaction (PGR) was set up to amplify 2 loci in each reaction. 
Each PCR mixture contained approximately 60 nano-grams extracted DNA, 0.33 
each primer, 10 mM Tris (pH 8.3), 50 mM potassium chloride, 2.5 mM magnesium 
chloride, 250 ^M each dNTP，and 0.6 units AmpliTaq Gold polymerase (Applied 
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Biosystems, Foster City, CA) in a total volume of 7.5 |j1 The PCR were performed in 
an ABI PRISM 877 integrated thermal cycler (Applied Biosystems, Foster City, CA). 
The PCR condition was 15 minutes at 95^C, followed by the first 10 cycles of 
denaturation at 94®C for 15 seconds, annealing at 55°C for 15 seconds, and extension 
step at 72°C for 30 seconds. The second 23 cycles were 15 seconds at 89®C, 15 
seconds at 55®C, and 30 seconds at 72°C. The final extension was performed at 72°C 
for 12 minutes. 
2. Electrophoresis 
The amplified PCR products for multiple loci were pooled together and resolved 
with gel electrophoresis. 2 [x\ of pooled PCR product was mixed with 3 |j,l of loading 
cocktail (2.5 fj.1 of deionized formamide and 0.5|li1 of Blue dextran/EDTA loading 
buffer). The samples were then denatured at 95^C for 5 minutes, immersed in ice cold 
water immediately. 2.5 p.! of the mixed product was loaded onto a prewarmed 5% 
polyacrylamide gel. 
Electrophoresis was conducted on an ABI PRISM 377 automated DNA sequencer 
(Applied Biosystems, Foster City, CA) for 2.5 hours at 200 W，60mA and 3000 volts, 
and analyzed with Genescan 2.1 software (Applied Biosystems, Foster City, CA). 
45 
3. Data Analysis 
The gel image was analyzed by the ABI Prism Genescan Analysis software. 
Normal sample with two distinct alleles at a particular marker was termed "informative" 
for that marker, because it was heterozygous at that locus. Normal sample with only one 
detected allele was termed non-informative, because it was homozygous at that locus. 
For each informative locus, the allelic ratio (AR) was calculated. AR was 
determined by measuring the peak height of the smaller allele (allele 1) to that of the 
larger allele (allele 2). The allelic imbalance (Al) value was defined as: AR of normal 
divided by AR of tumor. In this study, Al or LOH was defined by a decrease of either 
peak of at least 50%. Therefore, the Al values of less than 0.5 or greater than 2.0 were 
classified as Al or LOH. 
Raw data on BR21 showing homozygous, retention of heterozygosity and LOH is 
demonstrated on figure II-3. Calculations of AR and Al values based on the raw data 
are present on figure II-4. 
46 
A g A GeneScan^ai Gel Fle.x Display.21 
1400 1S0C 1800 2000 2200 3000 , 
MX. 
I 
1�". I 1 1 - I �J jvUi / L . / ^ L / \ _ � V -






” I I 
'� - I |! I I 
1 M M / l/A J I A � L 
_ 14 8:1<4R21T I PW.1-010S3ir.011SM».DlOS54«.DM1Me,DS8?»^S1«tr D10S217 D11S898 D10S548 D9S1826 D9S290 D9S1817 
Figure II-3. Raw data of six FAM-labeled microsatellite markers on BR21 in one lane. 
The normal tissue is on the top and the tumor tissue is on the bottom lane. D11S898 
( l lq) is homozygous. D10S548 (lOp) and D9S1817 (9p) show retention of 
heterozygosity. LOH is detected on D10S217 (lOq), D9S1826 (9q)，and D9S290 (9q). 
47 
D10S217 D10S548 
Tuiiiof Normal TumOf Normal 
11 I i I f i i n ^ 
jJL jUL Jlj, Jli-
AR=0.50 AR=1.08 AR=1.42 AR=1.60 
Al value = 2.16 (LOH) Al value = 1.13 (retention) 
D9S1826 D9S290 
Tumor Normal Tumor Normal 
1 “ i n I n n n r " 
A\\i/UI IMiK 
AR^.33 A R � . 3 2 AR=5.aO A R � . 2 7 
Al value = 0.14 (LOH) Al value = 0.25 (LOH) 
D9S1817 Tumor Normal 
A j y L i 
AR=1.62 AR=1.91 
Al value = 1.18 (retention) 
Figure iI-4. Deduction of AHeHc ratio (AR) and Allelic imbalance (Al) value. 
This is done on BR21 based on the raw data present on figure II-3. LOH is 
defined as Al value <0.5 or >2.0. The loss allele is illustrated by arrow in the 
figure. 
48 
CHAPTER III: RESULTS 
I. ALLELOTYPING ANALYSIS 
Twenty-six cases of local Chinese female primary invasive ductal carcinoma (IDC) 
of the breast were examined in the current study. Manual microdissection was 
conducted on all paired frozen tissue blocks to enrich the selected normal and tumor 
cells for comparison of allelic status. Cross contamination of normal and tumor cells 
were thus minimized. The percentages of neoplastic cells were estimated to be more 
than 80% after microdissection, and pure populations of normal constituents were 
obtained. These were confirmed by pathologists on microdissected sections before 
DNA extraction. 
Allelic status was comprehensively investigated with a panel of 382 
fluorescent-labeled microsatellite markers mapping to 22 human autosomes. A total of 
39 chromosomal arms were examined. The average interval of the microsatellite 
markers is approximately 10 cM. At least five loci of each of the 39 chromosomal 
arms were assessed. On each of the 39 examined chromosomal arms, at least one 
locus was informative on all twenty-six cases. The mean percentage of informative 
loci was 70% in this study. 
49 
The highest frequency of LOH amongst different loci was detected on the short 
arm of chromosome 17 by the marker D17S799, in which 15 out of 16 informative 
cases (93.8%) showed LOH. 
Absence of LOH was found at seven loci for all cases. They were D1S252 (Ip), 
D1S484 (Iq), D2S2368 (2p)，D4S1575 (4q), D6S1574 (6p), D12S1659 (12q), and 
D15S165(15q). 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































II. FREQUENCY OF LOH 
The frequencies of LOH on individual chromosomal arms ranged from 8% on 
chromosome 16p to 88% on chromosome 17p. This was calculated by the number of 
cases with LOH divided by the number of informative cases on particular chromosomal 
arms. The mean percentage of LOH was 35%, and the standard deviation (SD) was 
15%. High frequent affected chromosomal arms were defined as mean percentage 
plus one SD (35 + 15%). 
Chromosomes 17p (88%), 8p (62%), 16q (58%), Iq (50%), and 17q (50%) were 
classified as high frequent affected chromosomal arms. Other chromosomal arms with 
frequent LOH included Ip (46%)，8q (46%)，14q (46%)，22q (46%)，5q (42%), 6q 
(42%), lOq (42%), l lq (42%), 12q (42%), and 13q (42%). 






































































































































































III. FRACTIONAL ALLELIC LOSS 
Fractional allelic loss (FAL) is defined as the number of chromosomal arms with 
LOH, divided by the number of informative chromosomal arms. FAL for each tumor 
was calculated. FAL of the 26 breast cancer cases ranged from 8% to 67%, with a 
mean of 34.8% and a SD of 17.9%. No correlation between FAL value and the age, or 
tumor grade was found. 














































































IV. MINIMAL DELETION REGIONS 
Nine minimal deletion regions (MDR) were refined in the current high-resolution 
allelotyping analysis. Three of them were derived from chromosomes 8p and 16q, in 
which high frequent LOH were detected. Six of them were derived from chromosomal 
arms with frequent LOH. They were chromosomes 6q, 8q, lOq, 13q, and 14q. 
Although high frequencies of LOH were detected on chromosome 17p (88%), Iq (50%) 
and 17q (50%), no MDR could be identified. The current study showed that the whole 
arm of chromosome 17p was affected in most cases. 
The MDRs deduced from chromosomes 6q, 8p, 8q, lOq, 13q, 14q and 16q were 
shown on Table III-23 and Figure III-3 to Figure III-ll. 
72 
* 
Minimal Deletion LOH frequency on Chromosomal Arm Size (cM) Region chromosomal arm 
6q 6q24.1-25.2 8.6 42% 
8p 8p23.3-22 27.0 62% 
8p 8p21.3-12 20.0 62% 
8q 8q21.3-24.13 24.0 46% 
lOq 10q22.1-23.33 24.5 42% 
13q 13ql2.3-14.11 23.3 42% 
13q 13ql4.2-22.1 9.3 42% 
14q 14q22.3-24.2 19.2 46% 
16q 16q21-23.1 11.2 58% 
Table III-23: Minimal Deletion Regions Identified in Allelotyping Analysis 
73 
Chromosome lOq 
^ ^ ^ Markers 
"n —p 1 2 3 4 5 6 8 16 19 27 29 
100 D6S460 0 - 0 0 0 0 參 - - 0 -
9 3 D6S462 0 0 0 - 0 O - _ 0 
D6S434 0 - 0 0 0 0 # 0 0 0 
11.7 D6S287 0 - -參 O O - 鲁 - - -
II D6S262 - - - 0 0 - 0 • • 0 0 
91 D6S292 O O t O O O t O - 0 0 
8 6 D6S308 0 參 O O O O - 0 0 0 0 — T " 
D6S441 - 0 0 0 O 參 命 O -
0 D6S1581 • • 0 0 - - - - 0 0 
jQQ 068264 O 0 - - -
130 D6S446 0 • 0 _ - 0 • 0 O - -
~ ~ D6S281 0 - 0 參•參 0 0 0 0 參 
0 LOH 0 Retention - Non-informative 
CASE: BR 6 
Tumor Normal Tumor Normal Tumor Normal 
D6S292 jj D6S308 . D6S441 j i 
R mm ^ 圆 圓 L yy[|[ 
CASE: BR 3 
Tumor Normal Tumor Normal n n “ I I 
D6S308 D6S441 . i 
L bfi 圓 ^ iJuiJi 
— • : Loss allele 




一 2 5 6 8 11 12 14 16 19 21 22 25 27 28 29 30 
% D8S264 • • 舂 0 • • 鲁 0 春 0 0 0 0 0 0 0 
7 1 D8S277 參 拳 會 參 - • ( ) • 0 0 0 0 0 0 0 0 
D8S550 1 0 0 - 0 0 0 1 - - 0 0 • • 0 27.0 cM 
9-6 D8S549 . • - 0 _ 0 . 0 - 參 • • . . 0 -
100 D8S258 參參 Oo -鲁 0 . 0 0 - • 
9.8 n 
D8S1771 泰 • 眷 - - 春 - - 泰 - - -
_ D8S505 會 0 0 0 眷 0 舂 參 0 0 春 0 - 0 0 0 
0 LOH 0 Retention - Non-informative — • ： loss allele 
CASE: BR 8 
Tumor Normal , 酬 「 Normal 
D8S264 1 . I D8S277 ！ 
CASE: BR 16 
Tumor Normal Tumor Normal 
D8S550 . I D8S549 | I A ^ MM “ AA 




— 2 5 6 8 11 12 14 16 19 21 22 25 27 28 29 30 
% D8S264 . O O O I I I I I I O O O O O l 
7 1 D8S277 參0 0 0 - - i i o e o o i o o o 
D8S550 0 0 0 • 參 0 • 參 - - 0 0 - 0 0 
9 6 D8S549 . 0 - 0 0 0 - 0 - 0 - - - 0 -
100 D8S258 • • - - 0 0 0 0 •參 0 - 0 0 - 0 —r— 
9 8 
D8S1771 0 0 - - 0 - - - 0 - 0 - - 20.0 cM 
10.8 
D8S505 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 —'^― 
0 LOH 0 Retention - Non-informative — • : loss allele 
CASE: BR 16 
Tumor Normal Tumor Normal 
D8S258 I 1 D8S505 丨 l 1 
R LSJJU m i M 
CASE: BR 5 
Tumor Normal Tumor Normal 
\ D 8 S 5 0 5 - . 1 1 A 
L LMJLMJ R [AAjjAX 




c e n — 1 2 4 6 7 11 14 16 17 19 23 28 
D8S285 0 - 0 0 0 0 0 0 0 - - 0 
8 3 
D8S260 - 0 - 0 0 參 ® 0 0 0 0 24.1 
D8S270 0 0 - - - 0 參 0 0 0 - 0 
" 0 D8S1784 - 0 0 - - - 0 • - 0 - - 2 4 . 0 CM 
130 D8S514 0 0 0 0 - 0 - - 0 鲁 o i 
125 08S284 6 0 0 0 0 0 0 0 0 
124 麗 7 2 0 0 0 - 0 - 0 0 0 0 0 0 
0 LOH 0 Retention - Non-informative — • : loss allele 
CASE: BR 28 
Tumor Normal Tumor Normal 
D8S270 I I H I D8S514 j ‘ 
^ LAIAJ L Al y^l 
CASE: BR 4 
Tumor Normal Tumor Normal 
D8S1784 D8S514 I I 1 | 
L jL/IlM I ^ 關 L M L 




一 1 4 8 10 11 12 14 15 21 25 27 
D10S1% o - - o - - 0 0 0 0 0 
8.8 
12 3 D10S1652 O O " - O O • _ O -
D10S537 • O - O - - 0 • O O 
12-6 D10S1686 0 - 0 參 - - 0 0 0 0 0 24.5 cM 
D10S185 - O o - 0 - o O O • 
？、 D10S192 • 0 0 0 - 0 0 0 - 0 0 
4 . 1 
8 2 D10S597 O • O - - • " _ 0 O 
jQg DI0S1693 0 0 ^ - - - O Q - 0 0 -
D10S587 O - O O O O O O O O O 0 . 9 
j2 3 D10S217 0 0 0 0 0 - 0 0 0 參 
D10S1651 - 备 0 0 參 0 O • O O O 
D10S212 O - O - - - - - o 
• LOH 0 Retention - Non-informative ~ • : loss allele 
CASE: BR 10 
Tumor Normal Tumor Normal 
�7fflB— 
CASE: BR 8 Tumor Normal Tumor Normal r^n r^^ rrnrTT 
D10S1686 D10S185 | 
L LfUJ [iuU I洲歐 




cen 一 5 2 6 1 0 1 4 1 5 1 9 2 1 2 2 2 4 2 7 3 0 
D13S175 O Q O - 0 • O 0 O -
二 8 ——腳217 o - o — — o e o 0 0 5 
D13S171 - O • • - - O O O O O ^ — 
90 Dns2i8 - - 0 0 0 - - o - O - 23.3 cM 
69O5 ——Dns263 0 0 Q 0 - 0 # 0 0 - O ——D13S153 o # o e o o o o o o o 
� 6 D13S156 參 0 0 - 0 0 0 - 0 0 -
7 J D13S170 , - 參 - 0 0 眷 0 O - -
9 2 D13S265 � 0 0 0 - - 0 0 0 0 0 0 
7 9 D13S159 . 0 參 0 - - - ^ O O O O 
6.5 D13S158 e - O • • - 0 0 0 0 參 
60 = = D1細 - O O O - O O O O O O 
12.0 D13S1265 Q O O O O O O O O O 
D13S285 - 0 0 參 - 0 0 0 - 參 O 
0 LOH 0 Retention - Non-informative ~ • : loss allele 
CASE: BR 10 
Tumor Normal Tumor Normal 
D13S217 D13S171 / / ftft 
“ A A L AA 
CASE: BR 22 
Tumor Normal Tumor Normal 
:個回:囚区 




cen _ 2 6 lO 14 15 19 21 22 24 27 30 
D13S175 O O O - O O O O o -
二 D13S217 0 - 0 - - 0 0 0 O O O 
D13S171 - o o • - o o o o o 
9.0 D13S218 O O O - O O -
D,3S263 • 0 0 # - 0 # 0 0 O 
：： D13S153 O 參 O O O O O 0 0 鲁 O - 1 ~ 
I I D13S156 o O o - o o o - • O - -1—9.3 cM 
D13S170 . - O - 0 O o O • - -
9 2 D13S265 . O 拳 0 - - 0 0 0 0 0 0 
79 一 D13S159 0 0 0 - - - 參 O O O O 
6 5 D13S158 0 - 0 0 0 0 0 0 0 0 
6.0 D13S173 - 0 0 0 - 眷 0 0 0 0 0 
12.0 D13S1265 O O - O O O • 拳 O O O 
D13S285 . 0 0 0 - O O O - O 參 
0 LOH 0 Retention - Non-informative — l o s s allele 
CASE: BR 10 
Tumor Normal Tumor Normal 
CASE: BR 22 
Tumor Normal Tumor Normal Tumor Normal 
— I I m i I I I I I 
… 。 … \ D13S159 
D13S153 D13S265 , 
^ 圆圖 UUUU L IMA 




- n ^ 1 2 5 7 8 1 0 1 8 2 1 2 4 2 7 2 8 3 0 
D14S261 0 - 0 0 - 參 - 0 0 0 0 
； ’ — — D 1 4 S 2 8 3 ——0000000 - 0 -
D14S275 眷 0 - 0 0 - 0 0 0 - -
133 DI4S70 - - - 0 0 0 0 - - 0 0 -
； — — D U S 2 8 8 - 0 0 ——0 0 0 - 0 0 
二 ——D14S276 ——00-00000 - 0 _ 
14 3 DI4S63 • 0 0 0 0 0 0 0 0 0 0 19.2 cM 
4 9 • • • i H ^ i i 
130 D14S258 - 0 0 0 0 0 0 0 - 0 0 
8 9 D14S74 - 0 0 0 0 0 0 0 0 0 
78 D14S68 - 0 參 - - - 0 0 0 0 0 0 
JJ 3 D14S280 - # 0 - 0 0 0 0 0 0 
9 0 D14S65 0 9 0 0 0 0 0 - 0 0 0 
8.0 D14S985 0 0 0 - 0 0 鲁 0 - 0 0 D14S292 - 0 - 0 0 - 0 0 - - -
0 LOH 0 Retention - Non-informative — • : loss allele 
CASE: BR 5 
Tumor Normal Tumor Normal 
， 2 7 6 I •jlilLijd D，Lk�iJU-
CASE: BR 24 
Tumor Normal Tumor Normal 
t^h a i l A 1,63 圍 区 
CASE: BR 21 
Tumor Normal Tumor Normal 
T rorffl—r-jii i,m_— 




- — ‘ 1 2 6 7 8 10 15 16 21 23 24 25 27 28 30 
D16S3136 • - - 0 - - 0 0 - - 0 - 0 0 8.0 
D16S415 • - ( ) 參 0 0 0 Q 0 0 
80 D16S503 參 - 0 0 0 0 鲁 - - - 0 T i 1 2 C M 
旧 D16S515 0 0 0 ——00000 參 0 0 0 丄 
丨0 4 D16S516 . 0 - - 1 0 0 0 0 0 0 0 0 
110 D16S3091 • • 0 0 鲁 0 0 0 0 0 0 - 0 0 0 
14.0 
D16S520 6 參 0 會 參 - 0 0 0 0 0 0 參 0 0 
0 LOH 0 Retention - Non-informative — • ： loss allele 
CASE: BR 30 
Tumor Normal Tumor Normal 
D :側囡： 
CASE: BR 16 
Tumor Normal Tumor Normal 
D16S503 l\ D16S515 / h . 
Figure 111-11 : MDR at chromosome 16q21-23.1. 
82 
5. Chromosome 13q 
LOH of chromosome 6q was found in 42% of cases. An 8.6 cM MDR between 
D6S308 (6q24.1) and D6S441 (6q25.2) was delineated by cases BR6 (upper boundary) 
and BR3 (lower boundary). As demonstrated in figure 111-3，retention of both parental 
alleles was detected at D6S308，and LOH was found at D6S441 on BR6. The vice . 
versa was found on BR3. The break points centromeric to the upper boundary on BRI 
and BR3, and telomeric to the lower boundary on BRI and BRI6 further supported the 
defined MDR. 
2. Chromosome 8p 
Chromosome 8p was one of the most highly affected chromosomal arms in this 
study, with LOH frequency of 62%. Two MDRs were defined on the short arm of 
chromosome 8. The first 27.0 cM MDR between D8S264 (8p23.3) and D8S549 (8p22) 
was delineated by cases BR8 (upper boundary) and BRI6 (lower boundary). The 
second 20.0 cM MDR between D8S258 (8p21.3) and D8S505 (8pl2) was delineated by 
cases BRI6 (upper boundary) and BR5, BR6, and BR8 (lower boundary). The break 
points of these defined MDRs were illustrated in figure III-4 and figure III-5. 
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5. Chromosome 13q 
A 46% of cases showed LOH on chromosome 8q. A 24.0 cM MDR was delineated 
by BR28 (upper boundary) and BR4 (lower boundary) between D8S270 (8q21.3) and 
D8S514 (8q24.13). The break points centromeric to the upper boundary on BRl and 
BRl 7，and telomeric to the lower boundary on BR2 and BR14 further supported the 
defined MDR. However, the MDR defined on chromosome 8q might not be a true 
deletion region. This was because chromosome 8q had been shown frequently 
amplified in breast cancers and other neoplasms by CGH and FISH studies. This 
would be elaborated in the discussion section. The break points of the MDR detected 
were demonstrated in figure III-6. 
4. Chromosome lOq 
LOH was found in 42% of cases on chromosome lOq. A 24.5 cM MDR was 
delineated by BR4 and BRIO (upper boundary) and BR8 (lower boundary) between 
D10S537 (10q22.1) and D10S185 (10q23.33). The break points centromeric to the 
upper boundary on BRl 2 and BRl 5，and telomeric to the lower boundary on BRl and 
BRIO further supported the defined MDR. The MDR was shown in figure III-7. 
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5. Chromosome 13q 
Two MDRs were deduced from chromosome 13q, in which 42% cases of LOH 
were detected at this chromosomal arm. The first 23.3 cM MDR was delineated by 
BRIO and BR24 (upper boundary), and BR22 (lower boundary) between D13S217 
(13ql2.3) and D13S263 (13ql4.11). The second 9.3 cM MDR between D13S153 
(13ql4.2) and D13S156 (13q22.1) was delineated by BR22 (upper boundary) and BRIO 
(lower boundary). The MDRs were demonstrated in figure III-8 and figure III-9. 
6. Chromosome 14q 
A 46% of cases showed LOH on chromosome 14q. A 19.2 cM MDR between 
D14S276 (14q22.3) and D14S258 (14q24.2) was delineated by cases BR5, BR7，BR24, 
BR27 (upper boundary), and BR21 (lower boundary). The break points centromeric to 
the upper boundary on BRl, BRIO, BR18, BR21 and BR30, and telomeric to the lower 
boundary on BR7, BRIO, BRl8, BR24 and BR30 further supported the defined MDR. 
The break points of the MDR detected were demonstrated in figure III-10. 
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5. Chromosome 13q 
Chromosome 16q was the third most highly affected chromosomal arm in this 
study, with LOH frequency of 58%. An 11.2 cM MDR was defined on this 
chromosomal arm between D16S503 (16q21) and D16S515 (16q23.1). It was 
delineated by cases BRIO and BRl6 (upper boundary), and BR30 (lower boundary). 
The break points of the defined MDR were illustrated in figure III-ll. 
V. MICROSATELLITE INSTABILITY 
Microsatellite instability (MSI) was defined as shifts of bands on tumor samples 
comparing to normal controls. In contrast to LOH, only eight incidences of MSI on 
seven out of twenty-six samples were detected in the present study. They were 
detected on cases BRl (D5S424 at 5q), BR3 (D2S305 and D2S338 at 2p and 2q), BR4 
(D1S206 at Iq), BR6 (D3S1278 at 3q)，BRll (D6S434 at 6q), BR14 (DS1653 at lOp)， 
and BR29 (D11S987 at llq). No correlation between MSI and any observed 
parameters could be found. 
Examples of MSI were demonstrated on figure III-12 to illustrate two affected loci 







r n I i u L L 
Figure 111-12. Illustration of microsatellite instability (MSI) 
Two MSI are identified at D2S305 (chromosome 2p) and D2S338 (chromosome 2q) 
on BR3. MSI is manifested as a shift allelic band on tumor sample comparing to 
normal constituent. The shift allelic band is illustrated by arrow in the figure.. 
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CHAPTER IV: DISCUSSION 
Breast cancer is the third most common cancer worldwide (Parkin et al, 1999)，and 
being a major global public health problem. It is believed that a complex and 
heterogeneous set of genetic alterations is involved in the etiology of this disease. 
Tumorigenesis is now generally accepted as a multiple step process involving the 
activation of oncogenes and inactivation of TSGs (Vogelstein & Kinzler, 1993), instead 
of a single event. 
In order to reveal the genetic abnormalities of the sporadic breast cancer on local 
Chinese patients, a high-resolution allelotyping analysis of 382 fluorescent-labeled 
microsatellite markers mapping to 22 human autosomes on 26 cases of primary invasive 
ductal carcinoma (IDC) of the breast was performed. 
I. COMPARISON OF CHROMOSOMAL ALTERATIONS 
Comparable chromosomal alterations were observed in this study with published 
data on breast cancers. Comparison of affected chromosomal arms in breast cancers 
between a review article by Ingvarsson S (Ingvarsson, 1999) and the current study is 
shown in table IV-1. 
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Table IV-1: Comparison of Frequency of Affected Chromosomal Arms 
Chromosomal Arm Del/Amp (review) % of tumor % of tumor 
(review) (current study) 
Dei 36-54 46 
Iq Del/Amp 50-67 50 
^ Dei 34-45 ^ 
^ Dd 42 
^ Dei ^ 
^ Dei 47-58 ^ 
^ Amp 15 46 
^ Dei 38-58 f j 
Dd - 42 
n ^ Del/Amp 23-59 42 
Dd 3 3 ^ 42 
Dd 5 7 ^ ^ 
17p S S ^ 
17q Del/Amp 30-70 50 
Dd ^ 
^ Amp ^ 15 
^ Dd 40 46 
Del: deletion 
Amp: amplification 
Review: (Ingvarsson, 1999) 
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In the current study, the most frequently affected chromosomal arms observed are 
17p (88%), 8p (62%)，16q (58%), Iq (50%), and 17q (50%). Other frequent affected 
chromosomal arms are those with 46% LOH on Ip，8q, 14q, 22q, and with 42% LOH 
on 5q, 6q, lOq, llq, 12q and 13q. 
Kerangueven et al (Kerangueven et al, 1997) had performed a genome wide search 
for LOH on 75 human breast carcinomas by studying the allelic patterns of 184 
microsatellite markers distributed over all chromosomes. They had identified 56 
regions of consistent LOH, and the most frequently involved regions were on 
chromosome 8p, llq, 16q, and 17p. Chromosome 7q, once mentioned as a hotspot in 
breast cancer (Zenklusen et al, 1994)，was not confirmed by later studies (Devilee et al, 
1997). Kerangueven et al (Kerangueven et al, 1997) reported the LOH frequency on 
chromosome 7q was below 20%. The low incidence of affected chromosome 7q (23%) 
was also detected in the current study. 
Similar findings were also observed in studies on ductal carcinoma in situ (DCIS) 
of the breast, a preinvasive lesion of breast cancer. Radford et al (Radford et al, 1995) 
conducted an allelotyping analysis on 61 cases of DCIS by 56 microsatellite markers 
spanning on 39 autosomal arms. The highest frequency of LOH was observed on 
chromosome 17p (37.5%), 16q (28.6%), 8p (18.7%), 13q (18%), and 17q (15.9%). 
They proposed that the high incidence of LOH on chromosome 17p and 16q might be 
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involved in the development of breast cancer. 
Another microsatellite analysis on DCIS was conducted by Fujii et a\ (Fujii et al, 
1996). They studied 41 cases of DCIS without synchronous invasive cancer by 
microsatellite markers on ten chromosomal arms. They found that the number of 
allelic losses was significantly greater in lesions of intermediate or higher nuclear grade 
than in lesions of low nuclear grade. Not surprisingly, high frequency of LOH on 
chromosomes 17p and 16q was observed in both low nuclear grade DCIS, as well as in 
intermediate and high nuclear grade DCIS. This further supported chromosomal 
aberrations on 17p and 16q were common events in breast cancer development and 
occurred in an early stage. Besides, allelic losses of other chromosomal arms 
examined in that study (Ip, Iq, 6q, 9p, lip, llq, 13q, and 17q) were uncommonly seen 
in low grade DCIS, but were seen frequently in intermediate and high grade DCIS, 
implicating that those affected chromosomal regions were later events in breast 
carcinogenesis. 
A breath-taking study on Chinese population was conducted in Taiwan, a region 
close to Hong Kong, as well as characterized by low incidence of breast cancer (Yang et 
al, 1997) by Shen et al (Shen et al, 2000). They had performed a genome wide search 
for LOH using laser capture microdissected breast cancer tissue. In that study, 400 
microsatellite markers on 100 cases of breast cancer were analysed. The highest 
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frequencies of LOH were observed on chromosome Iq, 4p，8p, 8q，llq, 13q, 16q, 17p, 
17q, and 22q. These findings were comparable to the current study, in which 
chromosome Iq, 8p，16q, 17p，and 17q were classified as the most frequently altered 
chromosomal arms, and 8q, llq, 13q, and 22q were also frequently affected. The 
authors had also mentioned frequent LOH on chromosome 4p in their study objects, 
while this autosomal arm defect had rarely been mentioned in previous genome wide 
searches. They suggested that this chromosomal arm might be the site of 
ethnic-specific cancer susceptibility genes resided. In the current study, LOH frequency 
of 38% was detected on chromosome 4p，which was higher than the mean LOH 
frequency of 35%. The role of this chromosomal arm defect in breast cancer 
tumorigenesis on Chinese population may be desire for further investigations. 
II. MICROSATELLITE INSTABILITY 
Microsatellite instability (MSI) was frequently detected in colorectal cancers 
(Thibodeau et al, 1993) (lonov et al, 1993). MSI was defined as shifts of bands on 
tumor samples comparing to normal controls. Tumors demonstrating MSI were 
thought to have a replication error phenotype (Aaltonen et al, 1993). In contrast to 
LOH, the incidences of MSI were rare in the present study. There were only eight 
incidences of MSI on seven out of twenty-six samples detected. This was consistent 
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with infrequent MSI in breast cancer reported (Dillon et al, 1997) (Anbazhagan et al, 
1999). 
III. CHROMOSOMAL GAINS AND LOSSES 
LOH study has the problem on distinguishing between deletions and amplifications 
in tumor samples. In fact, the term of LOH does not merely explain as loss of genetic 
alleles. This is because chromosomal gains or amplifications can also be manifested 
as LOH pattern in the loci examined. The term of allelic imbalance (Al), a synonym 
to LOH, is widely used recently and may avoid the misleading impression of allelic loss 
in the term of LOH. 
Therefore, in defining MDR by allelotyping analysis，one important consideration 
is to determine if the region defined is a true loss, or attributable to chromosomal gains 
or amplifications. This can be done by careful examination on the genomic regions to 
see if they were reported as frequently amplified and harbored known oncogens through 
other research strategies such as CGH and FISH. 
Another approach to distinguish loss from amplification based solely on LOH 
analysis had been applied on breast cancer research (Hirano et al, 2001). This was 
done by normalizing each signal to the signal obtained when the same DNA was 
analyzed with markers for loci on other chromosomes. This may be dangerous and 
unreliable due to various intrinsic and extrinsic factors. Different oligo-primers, 
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end-product size, and even minor variation in the template DNA concentration may 
attribute to PCR performance, rendering comparison of signals between different 
markers not reliable. Therefore, in the current study, losses or gains of chromosomal 
regions were inferred by comparing previous CGH and FISH reports on breast cancers. 
By means of CGH and FISH analysis on primary breast cancers and breast cancer 
cell lines (Roylance et al, 1999) (Kuukasjarvi et al, 1997) (Forozan et al, 2000)，the 
most common regions of gain or amplification were on chromosomes Iq, 8q, 16p，17q, 
and 20q. Chromosomes Ip, 8p, llq, 13q and 18q were the most common regions of 
loss. 
However, the description of chromosomal regions as gain or loss does not 
necessarily imply that it was confined solely to oncogene activation, or TSG 
inactivation. This is because both oncogenes and TSGs may play in concert and reside 
within a small defined region. The chromosomal aberrations detected by a variety 
means of research methods may therefore just reflect the gross picture of the affected 
genomic areas. An example of this is noted on chromosome 17q, in which the TSG 
BRCAl is resided on 17q21.31, and the protooncogene ERBB2 is resided on 17qll.2-12. 
BRCAl inactivation (Rice et al, 2000) and ERBB2 amplification (Kauraniemi et al, 
2001) have been reported on breast cancers. As a result, LOH must be examined with 
caution when chromosomal gains or amplifications are likely to occur at those 
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susceptible regions. 
IV. CHROMOSOME 17 
High LOH frequencies were detected on chromosomes 17p (88%) and 17q (50%), 
in which the two well-known TSGs related to breast cancers, TP53 and BRCAl resided. 
However, no MDRs could be defined on both chromosomal arms. 
On chromosome 17p, the whole arm was affected in most of the cases therefore 
identification of MDR was impossible. TP53 resided on chromosome 17p 13.1 was the 
cancer hotspot, in which more than 50% of all cancers harbored TP53 mutations 
(Hollstein et al, 1991). However, the frequency was lower in breast cancers. A 
comprehensive meta-analysis revealed that only approximately 20% of all cases of 
breast cancers expressed mutant p53 (Pharaoh et al, 1999). In addition, LOH in the 
TP53 was shown to be a common event in primary breast cancers, but at least 60% of 
cases with LOH retained a wild-type TP53 allele (Davidoff et al, 1991). 
Interestingly, reduced p53 dosage might promote cancer formation and was proved 
in animal model (Venkatachalam et al, 1998)，strengthened the important role of TP53 
in tumorigenesis. The high LOH frequency on 17p in the current study suggested that 
TP53 might be the main target in this region. 
On chromosome 17q，both the TSG BRCAl and the protooncogene ERBB2 that 
related to breast cancer resided. In addition, a number of candidate genes that might 
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play roles in breast cancers were located on the long arm of chromosome 17. 
Examples were BRIPl (ARC4/-interacting protein 1), BCAS3 (breast carcinoma 
amplified sequence 3)，and NMEl (non-metastatic cells 1). However, no common 
deletion region could be defined based on the LOH pattern in the present study. 
V. MINIMAL DELETION REGIONS 
Nine minimal deletion regions (MDRs) on chromosomes 6q, 8，lOq, 13q, 14q，and 
16q were detected in this study. The objects were confined to invasive ductal 
carcinoma (IDC) of the breast on local Chinese populations. The MDRs deduced were 
mostly related to well-known tumor suppressor genes (TSGs) on different chromosomal 
regions, but oncogenes associated with breast cancer or undefined genes might reside on 
some of these regions. 
One detected MDR on chromosome 8q21.3-24.13 lied within the frequently 
amplified region where the known oncogene MYC resided. Examination on this region 
suggested that this was probably a region of amplification instead of a true deletion 
region. Therefore the region 8q21.3-24.13 is deselected from the nine MDRs. 
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1. Chromosome 6q 
In breast cancer, chromosome 6q21-qter is one of the most frequently deleted 
regions (Mertens et al, 1997). This was confirmed by a later study applying 
cytogenetic analysis and fluorescence in situ hybridization (FISH) analysis on benign, 
premalignant lesions and invasive carcinomas of the breast (Tibiletti et al, 2000), in 
which the interval between 6q24 and qter was the common region of deletion for these 
lesions. 
In the current study, the MDR was mapped to chromosome 6q24.1-25.2. The 
candidate region, 6q24-25, harbored a potential gene known to inhibit tumor cell 
proliferation. hZAC (Varrault et al, 1998)，LOT (Abdollahi et al, 1997b)，and PLAGLl 
(Kas et al’ 1998) referred to the same candidate TSG isolated independently and 
localized to the 6q24-25 region. Down regulation of ZAC was associated with 
spontaneous transformation in rat ovarian epithelial cells (Abdollahi et al, 1997a). The 
gene encoded a zinc finger protein widely expressed in human tissues, including the 
mammary gland (Spengler et al, 1997). hZAC was frequently inactivated in primary 
breast tumors, as well as in breast cancer cell lines and continually passaged cultures of 
normal human mammary epithelial cells (Bilanges et al, 1999). 
Recently, Zeller et al (Zeller et al, 2003) had identified a candidate TSQ called 
SAM and SH3 domain containing 1 (SASHl) on chromosome 6q24.3. SASHl was 
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downregulated in 74% of breast tumors in comparison with corresponding normal 
breast epithelial tissues. However, no mutation in the coding region of SASHl was 
found in breast cancers showing LOH within the critical region. They therefore 
hypothesized that other mechanisms such as hypermethylation of the gene might be 
responsible for the loss of expression of SASHl in the disease. 
Another target gene in this region was the estrogen receptor gene {ESR), which 
resided on 6q25.1. Growth of breast cancer could be stimulated by estrogens and 
inhibited by antiestrogens (Sommer et al, 2001). ESR might be related to breast cancer 
development and susceptibility to antiestrogen treatment. Nass et al (Nass et al, 2000) 
reported increasing frequencies of ESR methylation in DCIS (34%), IDC (52%), and 
locally advanced and metastatic breast cancer (61%). However genetic alterations, 
such as homozygous deletion, LOH or gene mutation had not been reported to be 
responsible for the loss of ESR expression (Yang X et al, 2001). Therefore the MDR 
detected in 6q24.1-25.2 in the current study might not be directed to ESR inactivation. 
J 
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5. Chromosome 13q 
The short arm of chromosome 8 was frequently affected in human cancers, such as 
breast (Yaremko et al, 1995) (Anbazhagan et al, 1998), prostate (Vocke et al, 1996), 
bladder (Takle & Knowles，1996)，and ovary (Wright et al, 1998). Breast cancer 
patients with LOH on chromosome 8p were expected to have a worse prognosis than 
patients without this defect (Sigbjomsdottir et al, 2000). LOH on 8p21.3-23 was 
reported as a common genetic alteration in infiltrating and in situ breast cancer 
(Anbazhagan et al, 1998). The pattern of deletion on 8p was complex, and a number 
of candidate genes had been suspected on this chromosomal arm on various neoplasms. 
LOH had been reported on chromosome 8p 12-23 in over 50% of primary breast 
cancers (Adelade et al，1998) (Wang et al, 1999). In the current study, LOH frequency 
of 62% was observed in this region, and two non-overlapping regions were identified. 
They were a 27 cM region on 8p23.3-22, and a 20 cM region on 8p21.3-12. 
A. 8p23.3-22 
Homozygous deletion within the region chromosome 8p23.3-22 had been reported 
on a variety of human cancers, including prostate (Arbieva et al, 2000)，head and neck 
(Sun et al’ 1999)，and medulloblastoma (Yin et al, 2002). Frequent LOH on 
chromosome 8p22-23.1 was observed in breast cancer and was expected contributing to 
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its progression (Yokota et al, 1999). 
The MSRl (macrophage scavenger receptor 1) gene is located on chromosome 
8p22. It may be a tumor susceptible gene, and germline mutations and sequence 
variants of MSRl are associated with prostate cancer risk (Xu et al, 2002). However, 
MSRl was expressed in macrophages only and did not appear to be a plausible 
candidate for a TSG in epithelial cancers (Emi et al, 1993). MSRl is therefore not 
likely to be the target gene in breast cancer. 
The LZTSl (leucine zipper, putative tumor suppressor 1) gene, or is called FEZl, 
resided on chromosome 8p22. Somatic mutation and altered transcript expression of 
LZTSl had been reported in a variety of human cancers, including gastric (Vecchione et 
al’ 2001), esophagus and prostate (Ishii et al, 1999). The LZTSl was thus thought to 
be inactivated by "two-hit" events including allelic loss, point mutations, and possibly, 
allelic loss plus shut-down transcription (Ishii et al, 2001). However, no point 
mutation was detected in breast cancer (39 primary breast cancers and 25 breast cancer 
cell lines), but FEZl expression was not detected (Ishii et al, 1999) in all breast cancer 
cell lines (n=15) and primary tumors (n=10). Further investigation of the role of 
LZTSl on breast carcinogenesis is needed. 
Another putative gene resided on chromosome 8p22 is the N33 (putative prostate 
cancer tumor suppressor) gene. It was isolated in the process of direct cDNA selection 
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of YAC clones encompassing the interval (MacGrogan et al, 1996). N23 was silenced 
by aberrant methylation in most colon cancer cell lines and some primary colorectal 
tumors. However, mutation analysis and sequencing of the 11 exons of N33 in 10 
metastatic prostate tumor samples did not show any mutations. Additionally, studies 
of N33 replacement in several colorectal lines failed to show evidence of tumor 
suppressor activity manifested as either in vitro inhibition of cell proliferation or 
suppression of nude mice (MacGrogan & Bookstein，1997). No N33 analysis was 
reported on breast cancer so far. 
B. 8p21.3-12 
The SFRPl (secreted frizzled-related protein 1) gene is resided on chromosome 
8pl2-pl l . l , which is a putative TSG encodes a member of a protein family that 
contains a cysteine-rich domain similar to the WNT-binding site of Frizzled receptors 
and regulates the WNT pathway (Ugolini F, 2001). The mRNA expression was lost in 
more than 80% of invasive breast carcinomas except the medullary type, comparing to 
normal expression in the epithelial component of normal breast and in the DCIS 
(Ugolini et al’ 2001). 
The BNIP3L (bcl2/adenovirus ElB 19kD-interacting protein 3-like) gene is located 
on chromosome 8p21, containing a sequence motif for a transmembrane domain and a 
101 
putative proapoptotic BH3 (Bcl-2 homology-3) domain (Yasuda et al, 1999). The 
possible tumor suppressor role of the BNIP3L gene was provided by experiments 
showing that the clonicity in soft agar of cervical cell lines was suppressed after 
transfection of the BNIP3L gene (Matsushima et al, 1998). Recently, Lai et al (Lai et 
al, 2003) analysed the BNIP3L gene in breast and ovarian cancer. They found similar 
expression of BNIP3L in cancer cell lines and respective normal epithelial cell lines of 
the breast and ovary by both RT-PCR and Northern analysis. No somatic mutation was 
found in 25 primary breast tumors examined (Lai et al, 2003). Therefore BNIP3L is 
unlikely to be the target of 8p LOH in breast cancer. 
Another candidate TSG involved in breast cancer is DBC2 (deleted in breast 
cancer). DBC2 contained a highly conserved RAS domain and two putative protein 
interacting domains, and was cloned from a homozygous deletion region at human 
chromosome 8p21 (Hamaguchi et al, 2002). Homozygous deletion in 7 out of 200 
breast tumors (3.5 %), and two instances of missense mutations within DBC2 in breast 
tumor specimens, but not in matched normals were reported by Hamaguchi et al 
(Hamaguchi et al，2002). In the same study, two missense mutations were also 
detected in one breast and one lung cancer cell lines, and expression of DBC2 was 
frequently extinguished in breast cancers but expression of a somatic mutant discovered 
in a breast cancer specimen did not suppress the growth of breast cancer cells. These 
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indicate that DCB2 is the best candidate TSG within the MDR identified in the current 
study and further investigation is highly desired. 
C. 8p22-21 
Three putative genes that may play roles on breast carcinogenesis are resided 
within the margins of the two MDRs identified in the current study. They are DLCl 
(deleted in liver cancer 1) gene on chromosome 8p22-21.3, TRAIL-Rl (tumor necrosis 
factor-related apoptosis-inducing ligand receptor 1) gene and TRAIL-R2 (tumor necrosis 
factor-related apoptosis-inducing ligand receptor 2) gene on chromosome 8p22-21. 
DLCl is a putative TSG frequently deleted in human liver cancer and has an 86% 
homology with rat pl22RhoGAP gene (Yuan et al, 1998). DLCl gene alterations were 
not confined to liver cancer but also found on a variety of human neoplasms. 
Promoter hypermethylation of DLCl was observed in a subset of liver, breast, colon, 
and prostate cancers (Yuan et al, 2003a). In addition, genomic deletion of DLCl was 
observed in 40% of primary breast tumors, whereas reduced or undetectable levels of 
DLCl mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell 
lines (Yuan et al, 2003b). Therefore DLCl may be a target on chromosome 8p 
associated with breast cancer and other human cancers. 
TRAIL-Rl and TRAIL-R2 genes had been investigated by Shin et al (Shin et al, 
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2001) on 34 and 23 breast cancers with and without metastasis to the regional lymph 
nodes respectively. They found that allelic loss of the chromosomal region TRAIL-Rl 
and TRAIL-R2 resided was significantly higher in metastatic breast cancers, and three 
TRAIL-Rl and four TRAIL-R2 mutations were detected only in the metastatic lesions. 
All seven mutations identified were missense variants caused by single-nucleotide 
substitution. This indicates that the chromosome 8p alterations in breast cancer may 
be appeared in early carcinogenic events, as well as in later tumor progressions. 
3. Chromosome 8q 
Chromosomal gains or amplifications of chromosome 8q were documented in 
breast cancer cell lines, primary and metastatic breast cancers by FISH and CGH studies 
(Forozan et al’ 2000) (Roylance et al, 1999) (Kuukasjarvi et al, 1997). In the current 
study a 24 cM MDR was identified on chromosome 8q21.3-24.13. 
The MYC gene, resided on chromosome 8q24.12-24.13，is one of the well-known 
oncogenes affecting a variety of human cancers (Nesbit et al, 1999). It is a key 
regulator of cell cycle progression from Gi into S phase, and its overexpression can 
induce either cell proliferation or apoptosis (Kreipe et al’ 1993). A review article of 
MYC on breast cancers stated a range of 1 to 94%, 15.5% on average, of breast cancer 
biopsies harbored MYC amplification of threefold or greater (Liao & Dickson，2000). 
Such variation in the frequencies might be due to the inconsistencies of the assay 
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methods, tumor grades, stages, and the number of cases studied. Despite the 
discrepancies of MFC alterations, its amplification might be an important biomarker and 
responsible for breast cancer development. 
In addition to the MYC gene, a number of genes or protooncogenes resided within 
the MDR 8q21.3-24.13 defined in the current study had been mentioned amplified, or 
overexpressed in breast cancer and other human neoplasms. They were the PTK2 
(PTK2 protein tyrosine kinase) resided on 8q24-qter (Agochiya et al, 1999), EBAG9 
(estrogen receptor binding site associated, antigen 9) at 8q23 (Tsuneizumi et al, 2002), 
CCNE2 (cyclin E2) at 8q22.2 (Geng et al, 2001), and E2F5 (E2F transcription factor 5, 
pl30-binding) at 8q21.1-21.3 (Polanowska et al, 2000). 
The evidence of previous reported frequent amplification of chromosome 8q, and 
several protooncogenes located within the affected region 8q21.3-24.13，suggest that 
this is a region of amplification instead of a true deletion region. Although location of 
TSG within this region cannot be excluded, the possibility is minimal. Therefore, the 
chromosomal region 8q21.3-24.13 is taken out from the nine MDRs detected in the 
current study. 
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5. Chromosome 13q 
LOH at chromosome 10q23-25 was a frequent event in a variety of human cancers, 
including breast (Bose et al, 1998) (Singh et al, 1998), glioblastoma (Maler et al, 1998)， 
and endometrium (lashiro et al, 1997). LOH at chromosome 10q23 had been observed 
in 40% (17/42) of invasive tumor but none in 20 cases of intraductal carcinoma of the 
breast (Bose et al’ 1998). 
In the current study, 42% cases showed LOH on chromosome lOq and a 24.5 cM 
MDR was defined at 10q22.1-23.33. One candidate TSQ PTEN (phosphatase and 
tensin homolog), or called MMACl (mutated in multiple advanced cancers 1) was the 
target gene in this region that resided on 10q23.3. 
PTEN encoded a dual-specificity phosphatase (Li et al, 1997)，and germline 
mutations were found in the autosomal dominant Cowden syndrome, which was 
characterized by multiple hamartomas involving many organ systems as well as an 
increased risk of developing breast and thyroid cancers (Liaw et al, 1997). 
Somatic mutations of PTEN were frequent in gliomas (Durr et al, 1998)， 
endometrial cancers (lashiro et al, 1997)，and melanomas (Tsao et al, 1998). In 
addition, promoter methylation of PTEN had been reported recently in endometrial 
cancer (Salvesen et al, 2001). 
Interestingly, unlike gliomas, endometrial cancers and melanomas, somatic 
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mutations of PTEN were rare in breast cancers (Bose et al, 1998) (Singh et al, 1998). 
Somatic mutations of PTEN were also rare in oriental areas too, such as Japan (Ueda et 
al, 1998) and Taiwan (Chen et al, 1999). 
To account for the MDR detected on chromosome 10q22.1-23.33 where LOH was 
frequent but the somatic mutation of the target gene PTEN was rare in breast cancers, 
several scenarios were possible. First, the easiest to say, is that other unknown TSG is 
resided within this region. Second, is that other PTEN inactivation mechanism such as 
promoter methylation, as reported on endometrial cancers (Salvesen HB, 2001. 91: 
22-26.) played a role. Thirdly, haploinsufficiency of PTEN is capable to drive the 
machinery of breast tumorigenesis. 
Haploinsufficiency and PTEN 
Haploinsufficiency refers to a phenotype associated with the inactivation of a 
single allele in a diploid organism (Cook et al, 1998). It is possible, at least for some 
genes, that deletion of one of its alleles, hence derangement of its dosage may have 
detrimental effects on normal cell development. This may be contradicted to the 
well-established Knudson "two-hit" hypothesis (Knudson, 1971), in which both alleles 
must be inactivated for tumorigenesis. However, Cook and McCaw have shown that 
loss of a single allele of a TSG can confer a selective advantage (Cook & McCaw， 
2000). 
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In fact, haploinsufficiency of PTEN has been reported on animal model that 
promotes cancer progression of prostate cancer (Kwabi-Addo et al, 2001). Therefore, 
if the phenomenon of haploinsufficiency of PTEN holds true in tumor progression, it 
will not be surprising that frequent LOH at 10q23.3, but rare somatic mutations of 
PTEN in breast cancer can play a role in breast cancer development. 
The evidence of haploinsufficiency of TSG to promote tumorigenesis is not 
restricted to PTEN. TP53 (Venkatachalam et a/, 1998), and ATM (Barlow et al, 1999) 
genes were also reported to exhibit the haploinsufFicient phenotype. Furthermore, the 
MAD2 haploinsufficiency had been reported to cause premature anaphase and 
chromosome instability in mammalian cells (Michel et al, 2001). It is no doubt that 
the number of TSGs with haploinsufFicient phenotype will be increasing, and more 
impacts on the Knudson "two-hit" hypothesis are coming. 
5. Chromosome 13q 
Previous studies on breast cancer had detected LOH frequency on chromosome 
13q varying from 30-63% (Hirano et al, 2001) (Clenton-Jansen et al, 1995) (Hamann et 
al，1996). In the current study, 42% cases showed LOH on chromosome 13q，and two 
common deletion regions at 13ql2.3-14.ll，and 13ql4.2-22.1 were identified. 
Two well-known TSGs, BRCA2 (13ql2-13) and RBI (13ql4) were located within 
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these regions. RBI alterations had been reported on breast cancers (Fung & T，Ang， 
1991) (Jares et ah 1997) (de Jong et al, 1998) (Bieche & Lidereau，2000). Germline 
mutations in the BRCA2 had been documented in breast cancer families (Tavtigian et al, 
1996), but rare at somatic level (Teng et al, 1996) (Miki et al, 1996). It is not clear if 
the BRCA2 is inactivated by other mechanisms, or the frequent deleted region is 
directed at other targets in sporadic breast cancers. 
6. Chromosome 14q 
LOH on chromosome 14q had rarely been mentioned on breast cancers. On the 
other hand, 14q deletion was common in a variety of human cancers, including lung 
(Abujiang et al，1998)，mesothelial (De Rienzo et ah 2000), brain (Simon et al, 1995), 
and nasopharynx (Lo et al, 2000). In the present study, 46% cases showed LOH on 
chromosome 14q, and a 19.2 cM MDR was mapped to 14q22.3-24.2. No candidate 
TSG related to breast cancer was spotted to this region. Another region, 14q31-32 had 
been mentioned on breast cancer with common LOH (O'Connell et al, 1999) (Martin et 
al, 2001)，which harbored the MTAl gene. LOH on this region might impede breast 
cancer metastasis but the exact role of MTAl had not be fully investigated. The 
common LOH on chromosome 14q detected on a variety of human cancers but rare 
candidate TSGs discovered rendering this chromosomal arm an interesting target for 
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further investigations. 
7. Chromosome 16q 
In the present study, chromosome 16q was the second most affected region (58%), 
comparing to chromosome 16p, which was the least affected one (8%). A 11.2 cM 
MDR was mapped on 16q21-23.1，which was located within another 32.6 cM common 
deletion region mapped on 16q21-23.3 in the current study, suggesting more than one 
TSG on chromosome 16q responsible for breast tumorigenesis. The proposal of 
multiple TSGs was supported by previous LOH analysis of chromosome 16q on breast 
cancer (Cleton-Jansen et al, 2001) (Skimisdottir et al, 1995) (Kouvaraki et al, 2001). 
The CDHl (E-cadherin) gene located on 16q22.1 was the target gene responsible 
for breast cancer. However, somatic CDHl mutations had been restricted to lobular 
breast tumors (Berx et al, 1995) (Berx et al, 1996)，but never on ductal type breast 
diseases. This might be accounted by other epigenetic change on CDHl. 
Hypermethylation of the CDHl CpG island had been reported in about 30% of DCIS, 
and significantly increased to 60% in breast cancer progression. (Nass et al, 2000). 
Another candidate TSG resided on the long arm of chromosome 16 was WWOX 
(WW domain-containing oxidoreductase) at 16q23.3-24.1. Pilot studies of WWOX on 
breast cancer revealed that homozygous deletion or mutation was rare (Bednarek et al, 
2000) (Driouch et al, 2002). However, reduced expression of the WWOX transcript in 
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a series of breast cancer cells and distinct alternative WWOX transcripts expressed at 
high levels in human tumors suggested an involvement of the WWOX gene in breast 
progression (Driouch et al, 2002). Considering the high incidence of LOH on 
chromosome 16q, further investigations on any candidate genes to breast cancers are 
desired. 
I l l 
CHAPTER V: CONCLUSION 
Allelotyping analysis revealed 26 cases of infiltrative ductal carcinoma of the 
breast in local Chinese female patients. Chromosomal arms with highest LOH 
frequencies were 17p (88%), 8p (62%), 16q (58%), Iq (50%)，and 17q (50%). Other 
chromosomal arms with frequent LOH were Ip, 8q, 14q，and 22q, observed in 46% of 
cases, and 5q, 6q，lOq, llq, 12q, and 13q, observed in 42% of cases. Eight minimal 
deletion regions ranging from 8.6 to 27.0 cM were defined on 6q24.1-25.2，8p23.3-22, 
8p21.3-12，10q22.l-23.33，13ql2.3-14.ll，13ql4.2-22.1, 14q22.3-24.2, and 16q21-23.1. 
This implied that several putative tumor suppressor genes on these regions might be 
associated with breast tumorigenesis. This information provided a background for 
further exploration on breast cancer biology. 
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